Drug delivery device and drug delivery system

Abstract

To provide a medicine administration device and a medicine administration system, capable of easily administering medicine via a subcutaneous infusion treatment.SOLUTION: A medicine administration device for subcutaneous administration of medicine comprises: a body part 21 configured to be disposed on a patient's skin; and a movement part 22 to which at least one needle member protruding toward the skin side is attached. The movement part is configured to be movable between a first position apart from the skin and a second position close to the skin. The medicine administration device is configured so that a tip of the needle member is inserted into the skin and the medicine is discharged from a hole provided on the needle member when the movement part is at the second position.SELECTED DRAWING: Figure 1

Description

[Technical field]

[0001] The present invention relates to a drug delivery device and a drug delivery system. [Background technology]

[0002] Peripheral intravenous infusion therapy, in which a drug contained in an infusion bag is administered to a patient's peripheral vein via a catheter, has been known for some time. However, depending on the patient's age, illness, or condition, it can be difficult to secure a peripheral vein, and there are also problems with the elderly, dementia patients, and children, including infants, who may bleed when they remove the needle themselves.

[0003] Subcutaneous infusion therapy has been reconsidered in recent years as an infusion therapy for these patients. Subcutaneous infusion therapy solves the problem of difficulty in securing peripheral veins, and has great advantages in other respects such as safety and manageability. As subcutaneous infusion therapy becomes more widespread in the medical field in the future, it is considered that products that respond to both the needs and risks of the medical field that will be required to be addressed are desired. For example, the drug administration device described in Patent Document 1 has a substrate from which multiple needle members connected to drug lines protrude, and is configured to be able to subcutaneously administer a drug by attaching this substrate to the skin and piercing the needle members into the skin. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] U.S. Patent No. 7,150,726 Summary of the Invention [Problem to be solved by the invention]

[0005] However, in the above device, the needle member is inserted into the skin at the same time as the substrate is attached to the skin, so the needle positioning and needle insertion must be performed at the same time, making the operation complicated. In addition, the needle member is exposed, which is a safety issue. Furthermore, it is thought that the exposed needle member creates a mental barrier for patients about inserting the needle member into the skin.

[0006] The present invention has been made to solve the above problems, and has an object to provide a drug administration device and a drug administration system that can easily administer a liquid drug subcutaneously. [Means for solving the problem]

[0007] The drug administration device of the present invention is a drug administration device for subcutaneously administering a drug, and comprises a main body configured to be placed on a patient's skin, and a movable part having at least one needle member attached thereto that protrudes toward the skin, the movable part being configured to be movable between a first position away from the skin and a second position close to the skin, and when the movable part is in the second position, the tip of the needle member is configured to be inserted into the skin, and the drug is configured to be expelled from a hole provided in the needle member.

[0008] According to this configuration, the needle member can be inserted into the skin by moving the moving part from the first position to the second position. Since the medicine can be discharged from the hole provided in the needle member, the medicine can be administered subcutaneously by simply moving the moving part to the second position. Therefore, for example, a medical professional or the patient himself can administer the medicine subcutaneously with a simple operation.

[0009] The needle member may be attached directly to the moving part, or indirectly via another member. The main body is placed on the patient's skin, but this includes not only direct placement, but also indirect placement via another member such as an adhesive.

[0010] In the above-mentioned medication administration device, the moving part may be configured to be held in at least one of the first position and the second position in a state in which no external force is applied.

[0011] According to this configuration, the needle member can be held in at least one of the states of being inserted into the skin and being separated from the skin without applying an external force, which makes the device easy to handle. If the device is configured so that it cannot be held in either position without applying an external force, it can be forcibly held in either position by using another tool such as a stopper.

[0012] The medicine injection device may further include at least one connecting part that connects the main body part and the moving part and is configured to be able to hold the moving part at least one of the first position and the second position. In addition, for example, the moving part may be held at either position by a member that is not connected to the main body part.

[0013] By connecting the main body and the moving part with the connecting part, for example, it is possible to reduce the number of parts in the final product. Also, by providing the connecting part, the position of the moving part can be maintained with a simple configuration.

[0014] In the above-mentioned drug administration device, the connecting portion can have various configurations, for example, it can be configured to surround the entire periphery of the needle member. When a plurality of connecting portions are provided, they can be radially arranged at predetermined intervals around the periphery of the needle member.

[0015] According to this configuration, since the multiple connecting parts are radially arranged at a predetermined interval, the moving part can be supported in a well-balanced manner in the circumferential direction, and therefore, problems such as the moving part tilting when moving between the first position and the second position can be suppressed.

[0016] In the above-mentioned drug administration device, each of the connecting parts is formed from an elastically deformable material and is configured to be in a first state in the first position and in a second state in the second position, each of the connecting parts is bent in the second state and is in a more extended state in the first state than the second state, and the connecting parts can be configured to transition between the first state and the second state with elastic deformation.

[0017] According to this configuration, the connecting portion is configured to transition between the first state and the second state with elastic deformation, so that the moving portion can be maintained in the first position or the second position unless an external force that causes elastic deformation acts on the connecting portion.

[0018] In this way, when a plurality of connecting parts are provided, for example, 2 to 10 connecting parts can be provided.

[0019] In the above-mentioned medication administration device, the main body portion, the moving portion and the connecting portion may be integrally formed.

[0020] According to this configuration, the main body, the moving part, and the connecting part can be handled as a single member, and the structure of the entire medicine injection device can be simplified, and therefore the number of parts can be reduced, leading to a reduction in manufacturing costs.

[0021] In the above-mentioned drug administration device, the main body portion, the moving portion, and the connecting portion can be formed from an elastically deformable elastomer, hard resin, or metal.

[0022] According to this configuration, when the needle member is made of an elastomer, it has high conformability to curved skin and can accurately puncture the skin, whereas when the needle member is made of a hard resin or metal, the device is stable against external forces.

[0023] In the above-mentioned medication administration device, the main body portion may be formed in a cylindrical shape, and the moving portion may be configured such that at least a portion of the moving portion is housed within the main body portion when in the second position.

[0024] According to this configuration, when the movable part is in the second position, the needle member is inserted into the skin while being housed in the main body part. Therefore, even if an external force is applied to the drug administration device during puncture, the effect on the needle member can be reduced, and the needle can be prevented from coming loose or breaking, or from moving while inserted into the skin.

[0025] The drug administration device is configured so that a drug line for supplying the drug can be attached, and the drug can be supplied to the needle member from the drug line.

[0026] This allows, for example, if the drug line is connected to a drug container such as an infusion bag, the drug can be administered over a long period of time.

[0027] The above-mentioned medicine administration device may further include an operating part that is connected to the moving part and can be held by a tool or a finger.

[0028] According to this configuration, by pulling the operation unit with a tool or a finger, for example, the moving unit can be easily moved from the second position to the first position.

[0029] The configuration of the operation portion is not particularly limited, but for example, the operation portion can be formed in a plate shape having an outer shape larger than that of the main body portion.

[0030] This allows the operating part to be made compact in the axial direction of the main body. Also, by making the operating part larger, it becomes possible to press the operating part with a finger over its entire surface during puncturing, which contributes to a stable puncturing operation.

[0031] The above-mentioned drug administration device may further include an extension portion connected to the operating portion, and the extension portion may be configured to cover at least a portion of the main body portion when the moving portion is in the second position.

[0032] According to this configuration, when the moving part is in the second position, the extension part is configured to cover at least a part of the main body part, so that the extension part can be brought into contact with the skin or placed in the vicinity of the skin. Therefore, in the second position, the operating part can be stably held. This allows the operating part to protect the entire main body part, and for example, when an impact or load acts on the operating part from the lateral direction, it is possible to prevent the moving part together with the operating part from shifting or floating up. Therefore, it is possible to prevent the needle member inserted into the skin from suddenly coming out or the needle member from moving while inserted into the skin.

[0033] In the above-mentioned drug administration device, the operating part can be configured to protrude radially outward from the outer periphery of the moving part, and can further include a stopper that is removably arranged between the operating part and the main body part when the moving part is in the first position, and that prevents the moving part from moving to the second position.

[0034] According to this configuration, the stopper is provided between the operating unit and the main body when the moving unit is in the first position. Therefore, the stopper can prevent the operating unit from unintentionally moving toward the main body and moving to the second position. Therefore, the moving unit can be held in the first position.

[0035] The drug injection device may further include a reservoir for storing a drug, and the drug may be supplied from the reservoir to the needle member. The drug may also be supplied to the reservoir from a drug line.

[0036] According to this configuration, for example, a small amount of drug such as insulin can be stored in the storage section. Then, when the moving section of the drug administration device is in the second position, for example, by applying pressure to the storage section, the drug in the storage section can be administered to the patient. Also, the drug can be supplied to the storage section from the drug line. In this case, the drug is normally supplied to the needle member from the drug line, but for example, if the supply of the drug from the drug line is suddenly cut off for some reason, the drug contained in the storage section can be discharged from the needle member, which prevents the administration of the drug from being interrupted and contributes to stable administration of the drug.

[0037] The above-mentioned drug administration device may further include a base that supports the main body portion and is placed on the skin.

[0038] This configuration allows the drug administration device to be fixed to the skin over a wide area, thereby enabling the device to be stably fixed to the skin.

[0039] The medication administration device may further comprise an adhesive material disposed on at least a portion of the surface of the base that contacts the skin.

[0040] According to this configuration, the base can be firmly fixed to the skin, making it possible to administer the drug over a long period of time.

[0041] In the above-mentioned drug administration device, a recess may be formed on the peripheral surface of the base facing the skin so that a gap is formed between the base and the skin.

[0042] According to this configuration, the recess allows a finger to be inserted between the base and the skin, making it easy to remove the base from the skin.

[0043] In the drug administration device, a plurality of drug administration units can be arranged on the base. The drug administration units can include the main body unit, the moving unit, and the needle member. In addition to the main body unit, the moving unit, and the needle member, the drug administration units can also include, for example, the above-mentioned connecting unit, as necessary.

[0044] This allows a large amount of drug to be subcutaneously administered in a short period of time. The drug administration portion may also include the above-mentioned connecting portion.

[0045] In the above-mentioned drug administration device, all of the moving parts of the plurality of drug administration parts may be configured to be connected to each other.

[0046] According to this configuration, since all the moving parts are connected, it is possible to move all the moving parts of the medicine administration parts from the first position to the second position, or from the second position to the first position, by one operation. Therefore, the work can be efficiently carried out. The moving parts can be connected, for example, by the above-mentioned operating unit.

[0047] The drug administration device may further include a base that supports the main body portion and is placed on the skin, and the base, the main body portion, the movable portion, and the connecting portion may be integrally formed from an elastomer.

[0048] According to this configuration, since the base placed on the skin is also formed of an elastomer, the base can be deformed and positioned so as to follow the skin surface. In addition, since the base is integrally formed with the main body, the moving part, and the connecting part, the main body, the moving part, and the connecting part can also follow the deformation of the base relative to the skin. Therefore, the needle member protruding from the moving part can be accurately protruded from the through hole of the base. Furthermore, even if the drug administration device is attached to the skin for a long period of time, the risk of the drug administration device peeling off from the skin can be reduced. In addition, the number of parts of the device is reduced, and the members consisting of the base, the main body, the moving part, and the connecting part can be produced by a method such as injection molding, which reduces manufacturing costs and simplifies disposal. In addition, the number of parts is reduced, making the structure simpler and easier to handle even for inexperienced users.

[0049] In the above-mentioned drug administration device, the main body portion is configured to be attached to the skin, and a recess can be formed in the main body portion so that a gap is formed between the main body portion and the skin.

[0050] According to this configuration, the recess allows a finger to be inserted between the main body and the skin, making it easy to remove the main body from the skin.

[0051] In the medicine injection device, the needle member may be fixed to the operating section, and the operating section may be configured to be detachable from the moving section together with the needle member.

[0052] According to this configuration, after the drug is subcutaneously administered, the needle member can be detached from the moving part by pulling the operation part from the main body part, which prevents the drug administration device from being reused and allows the needle member to be separately collected.

[0053] The medicine administration device may further comprise a detachment means for detaching the needle member from the main body portion.

[0054] According to this configuration, after the subcutaneous administration of the drug, the drug administration device is destroyed by the detachment means, making it possible to prevent the drug administration device from being reused and to separately collect the needle member.

[0055] The above-mentioned drug administration device may further include a cover member capable of covering at least the tip portion of the needle member, and may be configured such that when the moving part is in the second position, the tip portion of the needle member is exposed from the cover member, and after the moving part moves from the second position to the first position, the cover member covers the tip portion of the needle member and maintains the covered state.

[0056] According to this configuration, after the drug is subcutaneously administered and the moving unit is moved to the first position, the tip of the needle member is covered by the cover member and the covered state can be maintained. For example, even if the moving unit is moved from a state in which the needle member is covered by the cover member to a second position, the needle member is maintained in a covered state by the cover member, so that the needle member can be prevented from being used again.

[0057] In the medicine administration device, the tip of the needle member may be configured to be covered by the cover member when the medicine administration device is in the first position before use.

[0058] As a result, in the first position before use, the needle member is covered with the cover member before subcutaneous administration, so that the needle member can be prevented from coming into contact with other members, the human body, etc.

[0059] In the above-mentioned medicine injection device, the cover member may be configured to be detachable from the moving part together with the needle member.

[0060] This allows the needle member to be detached from the moving part together with the cover member after the drug is subcutaneously administered. This prevents reuse of the drug administration device and allows the needle member to be collected separately. In addition, since the needle member is covered with the cover member, it is possible to prevent contact with the needle member and prevent reuse of the needle member.

[0061] In the above-mentioned drug administration device, the thickness of the needle member is not particularly limited, but can be, for example, 30 gauge (outer diameter 0.30 mm) to 35 gauge (outer diameter 0.15 mm) in order to administer the drug efficiently.

[0062] In the drug administration device, the length by which the needle member protrudes from the surface where the drug administration device is fixed to the skin can be set to 1 to 10 mm (3 / 64 to 25 / 64 inch). This allows for effective subcutaneous administration of drugs to a wide range of patients, from infants to the elderly, taking into account individual differences in skin thickness.

[0063] The medication administration device may further include a housing portion configured to house at least the moving portion when the moving portion is in the second position.

[0064] According to this configuration, the storage section can prevent the movement section and the operation section in the second position from getting caught on clothing or the like.

[0065] In the above-mentioned medicine administration device, the needle member may be configured to be rotatable around an axis of the needle member relative to the moving part.

[0066] According to this configuration, for example, if a needle hole is formed on the side of the needle member or the tip of the needle member is cut at an angle, the needle member can be rotated around its axis to change the radial discharge position of the drug solution, which also makes it possible to adjust the liquid flow rate.

[0067] A first drug administration system according to the present invention comprises at least one drug administration device as described above, at least one drug container, and a drug line for supplying a drug from the drug container to each of the drug administration devices.

[0068] This first medicine administration system is suitable for administering a large volume of medicine, for example, an infusion liquid, etc. That is, an infusion liquid or the like can be stored in a medicine container and administered to a medicine administration device via a medicine line.

[0069] A second drug administration system according to the present invention includes at least one drug administration device described above, and a syringe capable of supplying a drug to the needle member.

[0070] This second drug administration system is suitable for administering a small amount of drug such as insulin, for example. That is, insulin or the like can be stored in a syringe and administered from the syringe to a drug administration device. Effect of the Invention

[0071] According to the drug administration device and drug administration system of the present invention, liquid drug can be easily administered subcutaneously. [Brief description of the drawings]

[0072] [Figure 1] FIG. 1 is a perspective view of a drug administration device according to a first embodiment of the present invention. [Diagram 2] FIG. 2 is a side view of FIG. [Diagram 3] FIG. 2 is a plan view of FIG. [Figure 4] FIG. 2 is a cross-sectional view of FIG. [Figure 5A] FIG. 2 is a cross-sectional view of a medication delivery device in a second position. [Figure 5B] FIG. 5B is a perspective view of FIG. 5A. [Figure 6] 2A-2C are diagrams showing examples of positions on the front and back of the body where the drug delivery device of FIG. 1 may be placed. [Figure 7] 2A to 2C are cross-sectional views showing a method of using the drug administration device of FIG. 1. [Figure 8] 2A to 2C are cross-sectional views showing a method of using the drug administration device of FIG. 1. [Figure 9] 2 is a cross-sectional view showing the medicine injection device of FIG. 1 with an operation unit and a needle member removed. FIG. [Figure 10] FIG. 2 is a perspective view of a medicine administration device according to a second embodiment of the present invention (first position). [Figure 11] FIG. 11 is a cross-sectional view of FIG. [Figure 12] FIG. 2 is a perspective view of the medication delivery device in a second position. [Figure 13] FIG. 13 is a cross-sectional view of FIG. [Figure 14] 1 is a cross-sectional view of a medication delivery device during transition from a first position to a second position; [Figure 15] 11A-11C are cross-sectional views showing a method of using the drug delivery device of FIG. [Figure 16] 11A-11C are cross-sectional views showing a method of using the drug delivery device of FIG. [Figure 17] 11 is a cross-sectional view showing the medicine injection device of FIG. 10 with an operation unit and a needle member removed. FIG. [Figure 18] 1. FIG. 4 is a perspective view showing another example of the medicine administration device of FIG. [Figure 19] FIG. 19 is a plan view of FIG. [Figure 20] FIG. 19 is a cross-sectional view of FIG. [Figure 21] 1. FIG. 4 is a cross-sectional view showing another example of the drug administration device of FIG. [Figure 22] 1. FIG. 4 is a cross-sectional view showing another example of the drug administration device of FIG. [Figure 23] 1. FIG. 4 is a cross-sectional view showing another example of the drug administration device of FIG. [Figure 24] 1. FIG. 4 is a cross-sectional view showing another example of the drug administration device of FIG. [Figure 25A] 1. FIG. 4 is a perspective view showing another example of the medicine administration device of FIG. [Figure 25B]1. FIG. 4 is a perspective view showing another example of the medicine administration device of FIG. [Figure 25C] 1. FIG. 4 is a perspective view showing another example of the medicine administration device of FIG. [Figure 25D] 1. FIG. 4 is a perspective view showing another example of the medicine administration device of FIG. [Figure 25E] 1. FIG. 4 is a cross-sectional view showing another example of the drug administration device of FIG. [Figure 26] 1. FIG. 4 is a cross-sectional view showing another example of the drug administration device of FIG. [Figure 27] 1. FIG. 4 is a side view showing another example of the medicine administration device of FIG. [Figure 28] 1. FIG. 4 is a side view showing another example of the medicine administration device of FIG. [Figure 29] 1. FIG. 4 is a side view showing another example of the medicine administration device of FIG. [Diagram 30] 1. FIG. 4 is a cross-sectional view showing another example of the drug administration device of FIG. [Diagram 31] 1. FIG. 4 is a cross-sectional view showing another example of the drug administration device of FIG. [Diagram 32] 32A-32C are cross-sectional views showing a method of using the drug delivery device of FIG. 31. [Diagram 33] 32A-32C are cross-sectional views showing a method of using the drug delivery device of FIG. 31. [Diagram 34] 32A-32C are cross-sectional views showing a method of using the drug delivery device of FIG. 31. [Diagram 35] 32A-32C are cross-sectional views showing a method of using the drug delivery device of FIG. 31. [Diagram 36] 1. FIG. 4 is a cross-sectional view showing another example of the drug administration device of FIG. [Figure 37] 37A-37C are cross-sectional views showing a method of using the drug delivery device of FIG. 36. [Figure 38] 1. FIG. 4 is a cross-sectional view showing another example of the drug administration device of FIG. [Figure 39] 39A-39C are cross-sectional views showing a method of using the drug delivery device of FIG. 38. [Diagram 40] 39A-39C are cross-sectional views showing a method of using the drug delivery device of FIG. 38. [Diagram 41] FIG. [Diagram 42] FIG. 42 is a perspective view showing a method of using the stopper in FIG. 41. [Diagram 43] FIG. 42 is a perspective view showing a method of using the stopper in FIG. 41. [Diagram 44] 1. FIG. 4 is a perspective view showing another example of the medicine administration device of FIG. [Diagram 45] FIG. 45 is a perspective view showing a method of using the drug delivery device of FIG. 44. [Diagram 46] FIG. 46 is a cross-sectional view of FIG. 45. [Figure 47] FIG. 46 is a cross-sectional view showing another example of FIG. 45. [Figure 48] 1. FIG. 4 is a cross-sectional view showing another example of the drug administration device of FIG. [Figure 49A] FIG. 2 is a perspective view showing another example of a drug administration device according to the present invention. [Figure 49B] FIG. 2 is a perspective view showing another example of a drug administration device according to the present invention. [Figure 50] FIG. 2 is a perspective view showing another example of a drug administration device according to the present invention. [Figure 51A] FIG. 1 is a side view showing another example of a medicine administration device according to the present invention (first position). [Figure 51B] FIG. 51B is a plan view of FIG. 51A. [Figure 51C] FIG. 51B is a side view of FIG. 51A (second position). [Figure 52A] FIG. 1 is a perspective view showing another example of a medicine administration device according to the present invention (first position). [Figure 52B] FIG. 11 is a perspective view showing another example of the medicine administration device according to the present invention (second position). [Figure 53A] FIG. 1 is a perspective view showing another example of a medicine administration device according to the present invention (first position). [Figure 53B] FIG. 11 is a perspective view showing another example of the medicine administration device according to the present invention (second position). [Figure 54A] FIG. 1 is a perspective view showing another example of a medicine administration device according to the present invention (first position). [Figure 54B]FIG. 11 is a perspective view showing another example of the medicine administration device according to the present invention (second position). [Figure 55A] FIG. 2 is a perspective view showing another example of a medicine administration device according to the present invention (first position). [Figure 55B] FIG. 55B is a front view of FIG. 55A. [Figure 56A] FIG. 11 is a perspective view showing another example of the medicine administration device according to the present invention (second position). [Figure 56B] FIG. 56B is a front view of FIG. 56A. [Figure 57A] FIG. 1 is a perspective view showing another example of a medicine administration device according to the present invention (first position). [Figure 57B] FIG. 11 is a perspective view showing another example of the medicine administration device according to the present invention (second position). [Figure 58A] 1 is a cross-sectional view showing another example of a medicine administration device according to the present invention (first position). [Figure 58B] FIG. 58B is a side view of FIG. 58A. [Figure 59A] 1 is a cross-sectional view showing another example of a medicine administration device according to the present invention (second position). [Figure 59B] FIG. 59B is a side view of FIG. 59A. [Figure 60A] 1 is a cross-sectional view showing another example of a medicine administration device according to the present invention (first position). [Figure 60B] 1 is a cross-sectional view showing another example of a medicine administration device according to the present invention (second position). [Figure 61A] 1 is a cross-sectional view showing another example of a medicine administration device according to the present invention (first position). [Figure 61B] 1 is a cross-sectional view showing another example of a medicine administration device according to the present invention (second position). [Figure 62A] 1 is a cross-sectional view showing another example of a medicine administration device according to the present invention (first position). [Figure 62B] 1 is a cross-sectional view showing another example of a medicine administration device according to the present invention (second position). [Figure 63A]Perspective view showing another example of the drug administration device according to the present invention. (First position) [Figure 63B] Perspective view showing another example of the drug administration device according to the present invention. (Second position) [Fig. 64A] Cross-sectional view showing another example of the drug administration device according to the present invention. (First position) [Fig. 64B] Cross-sectional view showing another example of the drug administration device according to the present invention. (Second position) [Figure 65A] Perspective view showing another example of the drug administration device according to the present invention. [Figure 65B] Perspective view showing another example of the drug administration device according to the present invention. [Figure 66] Cross-sectional view showing another example of the drug administration device according to the present invention. [Figure 67] Bottom-side perspective view showing another example of the drug administration device according to the present invention. [Figure 68] Cross-sectional view showing another example of the drug administration device according to the present invention. [Figure 69] Cross-sectional view showing another example of the drug administration device according to the present invention. [Figure 70] Perspective view showing another example of the drug administration device according to the present invention. [Figure 71] Cross-sectional view of FIG. 70.

Mode for Carrying Out the Invention

[0073] <A. First Embodiment> Hereinafter, a first embodiment of the drug administration device according to the present invention will be described with reference to the drawings. FIG. 1 is a perspective view (first position) of the drug administration device according to this embodiment, FIG. 2 is a side view of FIG. 1, FIG. 3 is a plan view of FIG. 1, FIG. 4 is an axial cross-sectional view of FIG. 1, FIG. 5A is a cross-sectional view of the drug administration device in the second position, and FIG. 5B is a perspective view of the drug administration device in the second position. Including the following first embodiment, the drug administration devices described in this specification are all used for subcutaneous administration of liquid drugs. The liquid drug can be, in addition to drugs with a large dosage such as infusion solutions like physiological saline, drugs with a small dosage such as antibacterial drugs and insulin. Also, the administration route is not limited to subcutaneous, and by adjusting the length of the needle of the drug administration device, it can be used for drug administration into the dermis, subcutaneous fat layer, and muscle layer. Hereinafter, this embodiment will be described in detail.

[0074] <A-1. Overview of the drug administration device> As shown in FIGS. 1 to 5, the drug administration device according to this embodiment includes a base 1 formed in a rectangular plate shape, and a drug administration unit 2 integrally formed on the base 1.

[0075] A circular through hole 11 is formed in the base 1, and the drug administration section 2 is provided so as to cover this through hole 11. An adhesive material 12 is applied to the lower surface of the base 1, and a release sheet (not shown) that covers this adhesive material 12 is attached before use. When the base 1 is large, the release sheet can be divided into a plurality of pieces and then attached to the adhesive material 12. The release sheet may be arranged so as to cover the through hole 11, or may be attached to the adhesive material except for the portion where the through hole 11 is formed. Instead of applying the adhesive material 12 to the lower surface of the base 1, an adhesive sheet or other sealing material may be attached to the lower surface of the base 1. Alternatively, the drug administration device can be fixed to the skin by attaching a tape such as an adhesive tape or a surgical tape from the base 1 to the skin without providing the adhesive material 12 on the base 1. In this case, the base 1 may be attached to the skin by tape after the base 1 is brought into contact with the skin, or the base 1 may have a tape attached to it from the beginning. Of course, the adhesive material 12 and the tape can be used in combination.

[0076] The drug administration unit 2 includes a cylindrical main body 21 attached to the base 1 so as to surround the through-hole 11, a cylindrical moving part 22 that can move in the axial direction within the internal space of the main body 21, and a connecting part 23 that connects the moving part 22 and the main body 21, all of which are integrally formed from an elastic material described later. Note that the axial direction refers to the direction of the axis of the cylindrical shape that constitutes the main body 21.

[0077] The connecting portion 23 is formed in a ring shape so as to connect the peripheral portion of the lower end of the moving portion 22 and the peripheral portion of the upper opening of the main body portion 21. The connecting portion 23 is formed in a band shape having a predetermined width between the main body portion and the moving portion. Therefore, as shown in FIG. 4, when the connecting portion 23 extends upward from the peripheral portion (first end) of the upper opening of the main body portion 21, the moving portion 22 is disposed in a position away from the base 1 (hereinafter referred to as a first position), and as shown in FIGS. 5A and 5B, when the connecting portion 23 extends downward from the peripheral portion of the upper opening of the main body portion 21, the moving portion 22 is disposed in a position close to the base 1 (hereinafter referred to as a second position). The second position may be a position where the lower end of the moving portion 22 enters the through hole 11.

[0078] When the moving part 22 moves between the two positions, the connecting part 23 is elastically deformed, so that the moving part 22 is held in each position so as not to move unless an external force is applied. On the other hand, when an external force is applied, the moving part 22 moves between the two positions. As shown in FIG. 5A, in this embodiment, when the moving part 22 is in the second position, the connecting part 23 extends from the upper opening of the main body part 21 toward the lower end of the moving part 22 without any load acting thereon (stable state). On the other hand, as shown in FIG. 4, when the moving part 22 is in the first position, the connecting part 23 is bent and extends upward (quasi-stable state). That is, an elastic load acts on the connecting part 23 in the first position. Therefore, when a downward force is applied to the moving part 22 in the first position, the connecting part 23 is elastically deformed so as to return to the stable state without being bent, and moves to the second position. Therefore, the moving part 22 moves quickly to the second position by the elastic force. The moving part 22 has an internal space that extends in the vertical direction and has an upper end and a lower end that are open to the outside, and a fixing part 32 of the operation part 3, which will be described later, is inserted into this internal space.

[0079] In this embodiment, the base 1, the main body 21, the connecting portion 23, and the moving portion 22 are integrally formed from an elastic material, and examples of the elastic material that can be used include elastomers such as silicone rubber, natural rubber, synthetic natural rubber, butadiene rubber, chloroprene rubber, and urethane rubber, as well as metals. For example, these can be molded integrally by injection molding.

[0080] The drug administration device further includes an operating section 3 and a needle member 4 attached to the operating section 3. The needle member 4 has an internal flow path along the axial direction. The operating section 3 includes a disk-shaped base 31 larger than the outer shape of the main body 21 and a cylindrical fixing section 32 protruding from the lower surface at the center of the base 31, which are integrally formed. A flange section 33 protruding radially outward is formed at the tip of the fixing section 32. A linear first passage 311 is formed from the outer periphery of the base 31 toward the center, and a linear second passage 321 is formed from near the upper end of the fixing section 32 to near the center in the axial direction. The end of the first passage 311 on the center side and the upper end of the second passage 321 are connected to each other, and an L-shaped passage is formed inside the operating section 3 as a whole. Furthermore, to supply a drug, a drug line 5 consisting of, for example, a tube, a bottle needle, a drip tube, a clamp, a connector, etc. is connected to the end of the outer periphery side of the first passage 311 via a connector (not shown: connecting the drug line to the operation unit). The drug line 5 may be detachably fixed to the operation unit 3 via the connector, or may be inseparably fixed to the operation unit 3. Furthermore, as will be described later, the connector does not have to be provided directly to the operation unit 3, and may be provided, for example, via a tube provided in the operation unit 3.

[0081] The above-mentioned needle member 4 is inserted and fixed at the lower end of the fixed portion 32, and extends to the second passage 321. Therefore, the medicine supplied to the first passage 311 is discharged from the hole provided in the needle member 4 via the second passage 321. The needle member 4 may have a thickness of, for example, 30 gauge (outer diameter 0.30 mm) to 35 gauge (outer diameter 0.15 mm). The hole provided in the needle member 4 includes a hole provided at the tip of the needle and a hole (side hole) provided beside the needle, and the position of the hole is not particularly limited. In addition, a plurality of holes may be provided.

[0082] The operation unit 3 can be formed from various materials, and can be formed from the same elastic material as the drug administration unit 2, or can be formed from a resin material such as a hard resin such as polypropylene, polyethylene terephthalate, or polyethylene. As a manufacturing method, for example, the needle member 4 can be insert molded together with the operation unit 3, or the needle member 4 can be fixed to the operation unit 3 by an adhesive means such as an adhesive. The needle member 4 can include a member composed of only a needle, as well as one composed of a needle and a needle hub. Therefore, the needle hub with the needle attached can be placed in a molding die and insert molding can be performed.

[0083] The operation unit 3 thus formed is fixed by inserting the fixing part 32 into the internal space of the moving part 22. At this time, the flange part 33 of the fixing part 32 protrudes radially outward from the lower end of the moving part 22, which acts as a retainer to fix the operation unit 3 to the moving part 22. When the operation unit 3 is fixed to the moving part 22, as shown in FIG. 4, when the moving part 22 is in the first position, the needle member 4 is accommodated inside the main body part 21, and as shown in FIG. 5A, when the moving part 22 is in the second position, the needle member 4 protrudes from the through hole 11 of the base 1. At this time, the length L of the needle member 4 protruding from the lower surface of the adhesive material 12 can be, for example, 1 to 10 mm (3 / 64 to 25 / 64 inch) for subcutaneous administration. Although the subcutaneous administration device of this embodiment has one needle member, it is also possible to have multiple needle members.

[0084] Note that the fixing method of the fixed part 32 to the moving part 22 is not particularly limited. For example, without providing a flange part 33, the fixed part 32 can be fixed by frictional force by press-fitting the fixed part 32 into the moving part 22, or the fixed part 32 can be fixed to the moving part 22 with an adhesive, or the fixed part 32 can be fixed to the moving part 22 by heat welding. Note that in the initial state, the moving part 22 is located at the first position, and in this state, after packaging and sterilization, it is shipped.

[0085] <A-2. Method of Using the Drug Administration Device> Next, the method of using the drug administration device configured as described above will be described. As described above, in the initial state, the moving part 22 is located at the first position. Then, the release sheet is peeled off from the base 1 to expose the adhesive material 12. Next, an infusion bag (not shown) containing the drug is connected to the drug line 5. Thereby, the drug discharged from the infusion bag is supplied to the needle member 4 via the drug line 5. Then, as shown in FIG. 7, after filling the drug line 5 and the needle member 4 with the drug, the adhesive material 12 is attached to the surface of the skin S to be subcutaneously administered. Note that the site where this device is attached and punctured is preferably a site with a large body surface area and sufficient subcutaneous space, such as the site indicated by the arrow in FIG. 6. Subsequently, the operation part 3 is pressed toward the base 1 side to move the moving part 22 to the second position. As a result, as shown in FIG. 8, the needle member 4 passes through the through hole 11 and quickly pierces the skin S, and the drug is subcutaneously administered from the needle member 4. Note that after attaching the base 1 to the skin, the drug line 5 and the infusion bag may be connected.

[0086] Thereafter, when a predetermined time has elapsed and the drug administration is completed, the operation part 3 is grasped with a finger and pulled upward. As a result, as shown in FIG. 7, the moving part 22 moves to the first position and the needle member 4 is pulled out from the skin S. Subsequently, the drug line 5 is removed and the base 1 is peeled off from the skin, and if necessary, the drug administration device is discarded. Here, the relationship of (the force required to move to the second position) < (the force required to move to the first position) is established, and thereby a stable puncture operation and needle withdrawal operation can be realized.

[0087] <A-3. Features of the drug administration device> As described above, according to this embodiment, by moving the moving part 22 from the first position to the second position, the tip of the needle member 4 can be projected from the through hole 11 of the base 1, and the needle member 4 can be inserted into the skin. And since the drug supplied from the drug line 5 can be discharged from the tip of the needle member 4, the drug can be subcutaneously administered only by moving the moving part 22 to the second position. Therefore, the patient and the user can subcutaneously administer the drug by a simple operation. In particular, the drug can be administered by an operation such as pushing in and pulling up the operation part 3, and since the needle member 4 is accommodated inside the main body part 21, for a user such as a patient, the psychological barrier of piercing and pulling out the needle can be reduced. Further, in this drug administration device, since the base 1, the main body part 21, the moving part 22, and the connecting part 23 are integrally formed of an elastic material, the structure can be simplified.

[0088] In the first position before use, since the needle member 4 is accommodated inside the main body part 21 and the tip of the needle member 4 is located above the base 1, it is possible to prevent the needle member 4 from accidentally piercing the patient before use. Therefore, it is highly safe and also hygienic.

[0089] Further, since the base 1 disposed on the skin is also formed of an elastic material, the base 1 can be deformed and disposed so as to follow the skin surface. Also, since the base 1 is integrally formed with the main body part 21, the moving part 22, and the connecting part 23 as a single member, the main body part 21, the moving part 22, and the connecting part 23 can also follow the deformation of the base 1 with respect to the skin. Therefore, the needle member 4 protruding from the moving part 22 can be accurately projected from the through hole 11 of the base 1, and the risk of the drug administration device peeling off from the skin can be reduced even when the drug administration device is worn on the skin for a long time.

[0090] In addition, since the adhesive material 12 is applied to the base 1, the drug administration device can be firmly held on the skin, and it is possible to reliably prevent the device from coming off the skin during drug administration over a long period of time.

[0091] Since the needle member 4 and the operation portion 3 are integrally formed, they can be removed from the moving portion 22 and discarded. Therefore, it is possible to prevent the drug administration device from being reused. And, as shown in FIG. 9, if other components, that is, the integrally formed base 1, the main body portion 21, the connecting portion 23, and the moving portion 22 are separated and collected, they can also be reused. Therefore, the total amount of waste can be reduced.

[0092] <B. Second Embodiment> Hereinafter, a second embodiment of the drug administration device according to the present invention will be described with reference to the drawings. The drug administration device according to the present embodiment is mainly different from the first embodiment in the configuration of the connecting portion, and since the other configurations are generally the same, the same reference numerals will be given to the same configurations and the description thereof will be omitted. FIG. 10 is a perspective view (first position) of the drug administration device according to the present embodiment, FIG. 11 is a cross-sectional view of FIG. 10, FIG. 12 is a perspective view of the drug administration device in the second position, and FIG. 13 is a cross-sectional view of FIG. 12. Hereinafter, the present embodiment will be described in detail.

[0093] <B-1. Outline of the Drug Administration Device> As shown in FIGS. 10 to 13, the drug administration device according to the present embodiment includes a base 1, a main body portion 21, a moving portion 22, and a plurality (four in the present embodiment) of connecting portions 23 that connect the moving portion 22 and the main body portion 21, and these are integrally formed of a resin material described later. Hereinafter, mainly the connecting portion will be described.

[0094] Each of the connecting parts 23 is formed in a plate shape and is arranged radially at equal intervals so as to connect the peripheral portion of the lower end of the moving part 22 and the peripheral portion of the upper opening of the main body part 21. Therefore, a gap is formed between adjacent connecting parts 23. More specifically, each connecting part 23 has a first part 231 and a second part 232, and the first part 231 and the second part 232 are connected to each other in a bent manner via a thin-walled bending part 233. In addition, the upper end of the first part 231 is connected to the lower end of the moving part 22 in a bent manner. In this way, each connecting part 23 is bent at two places including the connecting part with the moving part 22. As a result, the moving part 22 is movable between a first position shown in FIG. 10 and FIG. 11 and a second position shown in FIG. 12 and FIG. 13. The bent portion 233 is not limited to being formed by thinning a portion of the connecting portion 23, but may be formed by means of providing a cut or imparting a crease during manufacturing.

[0095] For example, in the first position shown in Fig. 10 and Fig. 11, the first part 231 of each connecting part 23 and the side surface of the moving part 22 (the side surface above the connecting part) are connected so that the angle α between them is an obtuse angle. Also, each connecting part 23 is bent so that the angle β between the first part 231 and the second part 232 across the bent part 233 is an obtuse angle (first state). As a result, the moving part 22 is supported above the main body part 21. At this time, the tip of the needle member 4 is located above the lower surface of the base 1. That is, as described later, the needle member 4 is held in a state where it does not puncture the skin.

[0096] 12 and 13, the first portion 231 of each connecting portion 23 is connected to the side surface of the moving portion 22 such that an acute angle α is formed. Also, each connecting portion 23 is bent at the bent portion 233 so that an acute angle β is formed (second state). As a result, the moving portion 22 is positioned lower than the first position, and at least a portion of the moving portion 22 is inserted inside the main body portion 21. As a result, the tip of the needle member 4 is positioned lower than the lower surface of the base 1. That is, as described later, the needle member 4 is held in a state of being punctured into the skin.

[0097] 14 is a cross-sectional view of the medicine injection device in the middle of transition from the first position to the second position. As shown in FIG. 14, in the first position, the horizontal distance D between the outer circumferential surface of the moving part 22 and the upper end of the second part 232 of the connecting part 23 is shorter than the length K of the first part 231. Therefore, when the moving part 22 moves from the first position to the second position, the second part 232 of each connecting part 23 elastically deforms so as to spread radially outward relative to the main body part 21, while the connecting part 23 is bent at an acute angle. Similarly, when the moving part 22 moves from the second position to the first position, the second part 232 of each connecting part 23 elastically deforms so as to spread radially outward relative to the main body part 21. Therefore, when the moving part 22 moves between the first position and the second position, an external force must be applied so that the second part 232 elastically deforms, and therefore the moving part 22 is held immovable when no external force is applied, that is, in the first and second positions. In other words, in each position, the moving part 22 is held immovable unless an external force that causes elastic deformation is applied. In addition, by making the relationship, for example, (force required to move to the second position)<(force required to move to the first position), stable puncture operation and needle removal operation can be realized, as described below.

[0098] In particular, when moving part 22 is pressed from above in the first position, second parts 232 elastically deform while connecting parts 23 bend, so that moving part 22 quickly moves to the second position. At this time, second parts 232 of connecting parts 23 elastically deform so as to uniformly expand radially outward, so that moving part 22 and needle member 4 move straight and parallel to the vertical axis, and as a result, needle member 4 punctures the skin perpendicularly.

[0099] The moving part 22 has an internal space that extends in the vertical direction and has an upper end and a lower end that are open to the outside, and a fixing part 32 of the operation part 3, which will be described later, is inserted into this internal space.

[0100] In this embodiment, the base 1, the main body 21, the connecting portion 23, and the moving portion 22 are integrally formed from an elastically deformable material. As such a material, in addition to the materials shown in the first embodiment, polyolefins such as polypropylene and polyethylene, polyesters such as polyethylene terephthalate, hard resins such as ABS, or metals can be used. In particular, the above-mentioned hard resins (polyolefins, polyesters, ABS, etc.) are preferable. In addition, hard plastics (plastics with a bending modulus or tensile modulus of elasticity greater than 700 MPa) specified in JIS K6900 can be used, and polypropylene, ABS, etc. correspond to hard plastics in this specification. Then, for example, these can be integrally molded by injection molding.

[0101] On the other hand, any one or more of the base 1, the main body 21, the connecting part 23, and the moving part 22 can be made of different materials. For the connecting part 23, for example, the bending part 233 can be made of a different material such as a known hinge, and the first part 231 and the second part 232 can be joined using a highly flexible member to make them movable.

[0102] In addition, this drug administration device is further provided with an operation unit 3 and a needle member 4 attached to the operation unit 3. Since these configurations are the same as those in the first embodiment described above, the description thereof will be omitted.

[0103] <B-2. Method of Using the Drug Administration Device> Next, a method of using the drug administration device configured as described above will be described. Generally, it is the same as that in the first embodiment. As described above, the moving part 22 is located at the first position in the initial state. Then, the release sheet is peeled off from the base 1 to expose the adhesive material 12. Next, an infusion bag (not shown) containing the drug is connected to the drug line 5. As a result, the drug discharged from the infusion bag is supplied to the needle member 4 via the drug line 5. Then, as shown in FIG. 15, after filling the drug line 5 and the needle member 4 with the drug, the adhesive material 12 is attached to the surface of the skin S to be subcutaneously administered. Note that the site where this device is attached and punctured can be the same as that in FIG. 6 described above. Subsequently, the operation unit 3 is pressed toward the base 1 to move the moving part 22 to the second position. As a result, as shown in FIG. 16, the needle member 4 passes through the through hole 11 and quickly pierces the skin S, and the drug is subcutaneously administered from the needle member 4. Note that after attaching the base 1 to the skin, the drug line 5 and the infusion bag may be connected.

[0104] Thereafter, when a predetermined time has elapsed and the drug administration is completed, the operation unit 3 is grasped with a finger and pulled upward. As a result, as shown in FIG. 15, the moving part 22 moves to the first position and the needle member 4 is pulled out of the skin S. Subsequently, the drug line 5 is removed, the base 1 is peeled off from the skin, and the drug administration device is discarded as necessary.

[0105] <B-3. Features of the Drug Administration Device> As described above, according to this embodiment, when the drug administration device is formed of a resin material such as a hard resin such as polypropylene, the moving part 22 is firmly supported by the connecting part 23, so that the displacement of the moving part 22 is stable. As a result, the trajectory of the needle tip from the first position to the second position is stable, and the needle member 4 can be prevented from piercing the skin obliquely. In this way, in order to elastically deform a resin material such as a hard resin, in this embodiment, a plurality of bendable connecting parts 23 are provided with gaps between the moving part 22 and the main body part 21, so that the connecting parts 23 can be deformed to an extent that they can be operated by the user by hand. In addition, since the connecting parts 23 are arranged radially at predetermined intervals, the connecting parts 23 are evenly deformed when the moving part 22 moves, and the moving part 22 can be supported in a balanced manner in its circumferential direction.

[0106] Since the needle member 4 and the operating section 3 are integrally formed, they can be removed from the moving section 22 and discarded, as shown in Fig. 17. This is the same as in the first embodiment.

[0107] The number of connecting parts 23 is not limited to four, and may be more than one. In particular, if the number of connecting parts 23 is increased, the moving part 22 can be stably supported, but if the number is too large, it becomes difficult to deform all of the connecting parts 23. Therefore, the number of connecting parts is preferably 2 to 10.

[0108] The configuration of the connecting portion 23 is not particularly limited, and it may be configured to be bendable at multiple locations. However, it is preferable that the connecting portion 23 is configured to undergo elastic deformation when transitioning between the first position and the second position. This allows the moving portion 22 to be held in the first position and the second position unless an external force that would cause elastic deformation is applied.

[0109] Alternatively, the movable portion 22 may be configured so as to be held in either position unless an external force is applied, for example, by using a jig or the like.

[0110] The location where the connecting portion 23 is provided is not particularly limited. As long as the moving portion 22 can be moved between the first position and the second position and the moving portion 22 and the main body portion 21 can be connected, the connection position is not particularly limited.

[0111] <C. Modification Example> As described above, the embodiments of the present invention have been described. However, the present invention is not limited to these embodiments, and various modifications are possible without departing from the spirit thereof. For example, the following modifications are possible, and the following modification examples can be combined as appropriate. Also, the configurations of each of the above-described embodiments and the following modification examples can be combined as appropriate.

[0112] <c-1> In the above embodiment, passages 311, 321 are provided in the operating unit 3, and the needle member 4 is inserted into and fixed to the fixed portion 32 of the operating unit 3. However, the configuration of the needle member 4 and the passages 311, 321 for supplying the drug to the needle member 4 is not particularly limited, and various configurations are possible.

[0113] For example, as shown in Figs. 18 to 20, a notch 312 is formed in the base 31 of the operation unit 3 at a portion corresponding to the first passage 311 described above, a connector (not shown) is provided in the notch 312, and a connector (not shown) on the drug line 5 side can be inserted into the connector. At this time, the needle member 4 can be formed into an L-shape, one end of which passes through the fixing portion 32, and the other end of which is inserted into the notch 312 along the radial direction. Then, the other end of the needle member 4 is inserted into the drug line 5 inserted into the notch 312. The needle member 4 can be fixed to the operation unit 3 by insert molding together with the operation unit 3 and the connector.

[0114] Alternatively, as shown in FIG. 21, a tube 6 is connected to the upper end of a straight needle member 4 so as to be perpendicular to the upper end, forming an L-shaped needle module 60 as a whole. At this time, the passage of the needle member 4 and the tube 6 are in communication with each other. The length of the tube 6 is made longer than the radius of the base 31 of the operation unit 3. Then, the needle module 60 is placed in a mold and insert molding is performed to form the operation unit 3. This allows the needle module 60 and the operation unit 3 to be molded integrally. Since the tube 6 of the needle module 60 protrudes from the outer edge of the base 31 of the operation unit 3, the drug line 5 can be connected to the connector 605 provided at the end of the tube 6. Note that a flow path as shown in FIG. 4 may be formed in the operation unit 3, and the tube 6, the flow path, and the needle member 4 may be in communication with each other.

[0115] In this way, the configuration for supplying the drug to the needle member 4 is not particularly limited, and as shown in FIG. 4 described above, a drug line 5 can be attached to the operation unit 3 and connected to an infusion bag. Also, as shown in FIG. 21, a tube 6 can be attached to the operation unit 3 or the needle member 4, and a drug line connected to an infusion bag can be connected to the tube 6 via a connector or the like. Alternatively, a tubing member connected to an infusion bag can be directly connected to the needle member 4. Therefore, in the present invention, a connection between the needle member 4, the moving unit 22, or the operation unit 3 and a drug supply source such as an infusion bag and supplying the drug corresponds to a drug line. Such a drug line can also be configured by connecting multiple tubing members.

[0116] <c-2> In the above embodiment, the operating unit 3, which has a larger outer shape than the main body 21, is connected to the moving unit 22, and the moving unit 22 is moved from the second position to the first position by being grasped with fingers. However, the configuration for facilitating the movement of the moving unit 22 is not limited to this. For example, the base 31 of the operating unit may be attached to a part other than the upper end of the moving unit 22, and may be formed in a flange shape that protrudes radially outward from the outer circumferential surface of the moving unit 22 (not shown). Also, as shown in FIG. 22, a wire 35 may be attached to the moving unit 22 as one aspect of the operating unit. The wire 35 may be molded and fixed integrally with the moving unit 22, for example, by insert molding. The wire 35 may also be molded integrally with the base 1, the main body 21, and the moving unit 22 by using the same material. In this way, if both ends of the wire 35 are fixed to the moving unit 22, the moving unit 22 can be easily moved from the second position to the first position by pulling the wire 35.

[0117] <c-3> In the above embodiment, the needle member 4 is integrated with the operation unit 3, so that they can be pulled and removed from the moving unit 22. However, the operation unit 3 is not necessarily required. For example, as shown in FIG. 23, the operation unit 3 may not be provided, and the above-mentioned needle module 60 may be fixed to the moving unit 22 by injection molding or the like. Alternatively, as shown in FIG. 24, a connector (not shown) may be provided at the upper end of the needle member 4, and the drug line 5 may be connected via this connector. In the aspects of FIGS. 23 and 24, the position can be moved by directly gripping or pushing the moving unit 22 with a finger. Therefore, the configuration of the moving unit 22 is not particularly limited, and it is sufficient that the moving unit 22 is configured so that the needle member 4 can be attached.

[0118] <c-4> In order to prevent the operation unit 3 having the needle module 60 from being collected separately or the drug administration device from being reused after the drug administration device of the present invention is detached from the skin after drug administration by the drug administration device, for example, the operation unit 3 can be pulled strongly to be removed from the moving unit 22. Also, as shown in FIG. 25A, a circular perforation 231 can be formed in the connecting unit 23 so that the operation unit 3 having the needle module 60 can be torn off together with the moving unit 22. As a result, as shown in FIG. 25B, the connecting unit 23 is broken, and the moving unit 22 is detached from the main body 21 together with the needle member 4. Alternatively, as shown in FIG. 25C, a circular breaking portion 232 formed by a perforation can be formed in the connecting unit 23, and the breaking portion 232 can be detached from the connecting unit 23 by pulling the end 233 of the breaking portion 232 protruding from the connecting unit 23. As a result, as shown in FIG. 25D, the connecting unit 23 is separated, and the moving unit 22 can be detached from the main body 21. 25E, a handle 36 may be formed on moving part 22 or connecting part 23 so that operating part 3 having needle module 60 can be torn off together with moving part 22 by pulling handle 36. The perforations and handle 36 constitute the detachment means of the present invention.

[0119] <c-5> In order to make it easier to peel the base 1 from the skin, for example, as shown in Fig. 26, a recess 14 can be formed on the underside of the base 1 so that a gap is formed between the base 1 and the skin. This allows a finger to be inserted into the gap where the recess 14 is formed, and the base 1 can be grasped with the finger and peeled off from the skin. Also, the adhesive material 12 can be not applied to the recess 14, making it even easier to insert the finger. Alternatively, the recess 14 can be omitted, and the adhesive material can be not applied to the portion where the recess 14 should be formed, thereby allowing the finger to be inserted into the portion where the adhesive material is not applied.

[0120] In the above embodiment, the base 1 is fixed to the skin by the adhesive material 12, but the adhesive material 12 does not have to be applied to the entire lower surface of the base 1, and may be applied only to a part of the lower surface. Also, the base 1 is not limited to the adhesive material, and can be fixed to the skin by, for example, tape or the like.

[0121] The size, shape, and thickness of base 1 are not particularly limited as long as it can be placed on the skin and has through-hole 11. Also, base 1 can be formed separately from drug administration section 2, and drug administration section 2 can be fixed onto base 1 by adhesive, thermal welding, or the like.

[0122] <c-6> In the above embodiment, one drug administration unit 2 is provided on base 1, but multiple drug administration units 2 may be provided as shown in Figure 27. This allows a large amount of drug to be subcutaneously administered in a short period of time.

[0123] 28, a plurality of branch lines 51 branched from one drug line 5 can be connected to each drug administration unit 2. Also, a portion of drug line 5 and branch line 51 can be fixed to base 1 and integrated with base 1. This can prevent lines 5, 51 from becoming entangled and from adhering to adhesive 12.

[0124] As shown in FIG. 29, one operation unit 30 can be attached to a plurality of drug administration units 2. In this way, by pushing the operation unit 30, all the moving units 22 can be simultaneously moved from the first position to the second position, and by pulling the operation unit 30, all the moving units 22 can be simultaneously moved from the second position to the first position. When a plurality of drug administration units 2 are used in this way, a plurality of needle members 4 can be provided. Furthermore, the drug administration device of the present invention can be combined with at least one drug container (infusion bag) containing a drug, at least one drug line connecting the drug container and the drug administration device, and the like to form a drug administration system. The drug administration system can be used to administer a drug by simultaneously piercing 1 to 20 needle members 4 into the skin in one drug administration using one or more drug administration devices having one or more drug administration units 2. The drug administration system can be a drug administration system using preferably 1 to 10 needle members, more preferably 1 to 5 needle members in one administration. In this case, a plurality of needle members 4 can be provided in the moving unit 22 in one drug administration unit 2. Furthermore, the number of drug lines is not particularly limited, and the same number of drug lines as the drug administration units 2 may be provided, or a branched drug line connectable to a plurality of drug administration units 2 (for example, see FIG. 28) may be used. Furthermore, the number of infusion bags is also not particularly limited, and drugs can be supplied from a plurality of infusion bags to a plurality of drug administration units 2. When a plurality of drug administration devices are used, the application site (puncture site) can be appropriately selected from application sites such as the abdomen, chest, thigh, back, and upper arm, and the drug administration devices can be spaced apart from each other for administration.

[0125] <c-7> In the above embodiment, the drug is supplied directly from the drug line 5 to the needle member 4. However, for example, as shown in FIG. 30, a drug storage section 38 can be provided between the needle member 4 and the drug line 5. A closed space 381 is formed in the storage section 38 to store the drug supplied from the drug line 5, and the needle member 4 is connected to the closed space 381. Therefore, for example, even if the supply of the drug from the drug line 5 is stopped for some reason, the drug stored in the storage section 38 is supplied to the needle member 4, so that the drug can be stably administered subcutaneously. In the case of a subcutaneous administration device having the storage section 38 in this way, even if the number of needle members is multiple, only one line is required, and problems such as entanglement of the lines do not occur. It is also possible to administer only the drug stored in the storage section 38 without providing the drug line 5 in the storage section 38.

[0126] <c-8> In the above embodiment, a mechanism for covering the needle can be provided to prevent reuse of the needle member 4 once used and to prevent erroneous puncture. For example, as shown in FIG. 31, a cylindrical cover member 8 is attached around the fixed portion 32 of the operation unit 3, and in this state, the operation unit 3, the needle member 4, and the cover member 8 are attached to the moving unit 22. The cover member 8 includes an outer tube 81 and an inner tube 82 that are generally concentric and have approximately the same axial length, and in the initial state, the inner tube 82 is accommodated in the outer tube 81. In addition, the outer peripheral surface of the outer tube 81 is fixed inside the moving unit 22. However, if the outer tube 81 is pulled up strongly, it will detach from the moving unit 22. The inner tube 82 is adapted to slide in the axial direction along the outer tube 81, and the cover member 8 has a locking mechanism (not shown) that locks the lower end of the outer tube 81 and the upper end of the inner tube 82 to each other.

[0127] The upper end of the outer cylinder 81 is fixed to the lower surface of the base 31 of the operating unit 3, and the lower end of the inner cylinder 82 is fixed to the lower end of the moving unit 22 in a state where it protrudes slightly from the outer cylinder 81. That is, a flange portion 821 protruding radially outward is formed at the lower end of the inner cylinder 82, and this flange portion 821 engages with the lower end of the moving unit 22.

[0128] According to this configuration, when the operating unit 3 is pressed downward from the first position, the moving unit 22 moves downward together with the cover member 8 and the needle member 4, as shown in FIG. 32, and the needle member 4 passes through the through hole 11 of the base 1 and is inserted into the skin. When the operating unit 3 is grasped and pulled upward from this state, the moving unit 22 moves together with the cover member 8 and the needle member 4 to the first position, as shown in FIG. 31. When the operating unit 3 is further pulled upward from this state, the outer tube 81 is released from the moving unit 22, and the inner tube 82 is slid and pulled upward, as shown in FIG. 33. At this time, since the flange portion 821 of the inner tube 82 is engaged with the lower end of the moving unit 22, the inner tube 82 remains in the moving unit 22. Then, when the lower end of the outer tube 81 is locked to the upper end of the inner tube 82, the outer tube 81 and the inner tube 82 are connected in the axial direction, and the cover member 8 expanded in the axial direction is formed. As a result, the needle member 4 is housed in the expanded cover member 8 and is not exposed to the outside. In addition, because the outer tube 81 and the inner tube 82 are locked, the expanded cover member 8 does not return to its initial state even if the operating part 3 is pushed in. Therefore, the needle member 4 remains housed in the expanded cover member 8, preventing it from being used again and preventing accidental punctures with a used needle member, which leads to the prevention of infection.

[0129] In the example shown in FIG. 31, the inner tube 82 is housed in the outer tube 81 when the moving part 22 is in the first position. However, as shown in FIG. 34, for example, when the moving part 22 is in the first position, the inner tube 82 can be protruded below the moving part 22 to cover the needle member 4. This can reliably prevent the patient and other users from touching the needle member 4 before use. When the operating part 3 is pressed, the flange part 821 of the inner tube 82 is pressed against the skin, and the inner tube 82 slides and is housed in the outer tube 81 as shown in FIG. 32. When the operating part 3 is then pulled up, the moving part 22, the outer tube 81, and the inner tube 82 are lifted up together as shown in FIG. 31. If the lower end of the outer tube 81 and the upper end of the inner tube 82 are configured to lock when the operating part 3 is pulled up further, the needle member 4 is housed in the inner tube 82 as shown in FIG. 33.

[0130] If the operating unit 3 is further pulled up with a strong force, the flange portion 821 of the inner tube 82 comes off the lower end of the moving unit 22 as shown in Fig. 35, and the cover member 8, needle member 4, and operating unit 3 can be detached from the moving unit 22 and collected separately. This prevents the medicine administration device and needle member 4 from being reused and prevents accidental puncture. At this time, the needle member 4 can be maintained housed in the cover member 8, preventing infection and the like.

[0131] In the embodiment of Figs. 31 to 35, the cover member 8 is composed of an inner tube 82 and an outer tube 81, but the cover member can also be composed of only the inner tube. For example, in the example of Fig. 36, a cylindrical cover member 9 is fixed to the internal space of the moving part 22. This cover member 9 has a flange portion 92 formed at the lower end, and this flange portion 92 engages with the lower end of the moving part 22. In addition, an annular protrusion 91 is formed at the upper part of the inner wall surface of this cover member 9. And, the fixing part 32 of the operation part 3 is slidably inserted inside this cover member 9. In addition, an annular groove 34 is formed at the lower part of the outer circumferential surface of the fixing part 32, and the protrusion 91 of the cover member 9 can be engaged with this groove 34.

[0132] In the above configuration, when the operating unit 3 is pulled up from the state shown in FIG. 36, the fixed part 32 slides upward as shown in FIG. 37. Then, when the protrusion 91 of the cover member 9 engages with the groove 34 of the fixed part 32, the operating unit 3 cannot be pulled up any further. That is, the groove 34 and the protrusion 91 form a mechanism to prevent the fixed part 32 from coming out of the cover member 9. In this state, the needle member 4 is housed in the cover member 9. If the operating unit 3 is pulled up strongly from this point, the flange part 92 of the cover member 9 comes off the moving part 22, and the operating unit 3, the cover member 9, and the needle member 4 are released from the moving part 22 with the needle member 4 housed in the cover member 9, as shown in FIG. 35. Therefore, the cover member 9, the needle member 4, and the operating unit 3 can be collected separately, and reuse of the medicine administration device and the needle member 4 and erroneous puncture are prevented. The means for engaging the pulled-up fixing portion 32 with the cover member 9 is not particularly limited, and various types of retaining mechanisms other than those described above can be applied.

[0133] In addition, the following configuration can be adopted to prevent reuse of the medicine administration device and the needle member 4. For example, as shown in FIG. 38, a male thread is formed on the outer peripheral surface of the fixed part 32 to which the needle member 4 is attached, and this is housed in a cylindrical cover member 88 having a female thread formed thereon. The axial length of the cover member 88 is set to about half that of the needle member 4, and the needle member 4 is made to protrude from the tip of the cover member 88 while the fixed part 32 is rotated around the axis together with the needle member 4. Then, this cover member 88 is fixed to the moving part 22. However, if the cover member 88 is pulled up strongly, it is configured to be detached from the moving part 22. In addition, since a flange part 881 is formed on the lower end part of the cover member 88, the flange part 881 of the cover member 88 and the lower end of the moving part 22 can be engaged with each other.

[0134] In such a drug injection device, after the subcutaneous injection of the drug shown in FIG. 39 is completed, the moving part 22 is moved from the second position to the first position, and then the fixed part 32 is rotated around the axis together with the needle member 4 from the state of FIG. 38. As a result, as shown in FIG. 40, the needle member 4 moves upward together with the operating part 3 inside the cover member 88 while rotating around the axis. Then, when the tip of the needle member 4 is completely housed in the cover member 88, the rotation stops. As a result, the state in which the needle member 4 is housed in the cover member 88 is maintained, and even if the operating part 3 is pushed downward from this state, the needle member 4 is not exposed. Therefore, the needle member 4 is prevented from being used again. It is also possible to lock the rotation by rotating the needle member 4 until the tip of the needle member 4 is completely housed in the cover member 88. Then, when the operating part 3 is strongly pulled up from the state of FIG. 40, the cover member 88 is released from the moving part 22, and the cover member 88, the needle member 4, and the operating part 3 can be separately collected. As a result, it is possible to prevent reuse of the medicine administration device and the needle member 4 and to prevent accidental puncture. Note that a luer lock may be used instead of the screw.

[0135] <c-9> In the above embodiment, a stopper for holding the moving part 22 at the first position may be provided. As shown in FIG. 41, the stopper 95 includes a cylindrical stopper body 951 and a knob part 952 attached to the outer circumferential surface of the stopper body 951, and is made of a resin material or the like. The stopper body 951 has a cutout part 953 extending in the axial direction formed in a part of the circumferential direction, and is formed into a C-shape in a plan view as a whole. The inner diameter of the stopper body 951 is formed to be slightly larger than the outer diameter of the moving part 22 and smaller than the outer diameters of the base part 31 and the main body part 21 of the operating part 3. The circumferential width of the cutout part 953 is smaller than the outer diameter of the moving part 22.

[0136] As shown in FIG. 42, the stopper 95 is inserted between the operation unit 3 and the main body 21 when the moving unit 22 of the medicine injection device is in the first position. Then, the cutout portion 953 of the stopper body 951 is opened and arranged to cover the outer peripheral surface of the moving unit 22. As a result, as shown in FIG. 43, the stopper body 951 is arranged between the base 31 of the operation unit 3 and the main body 21, and the operation unit 3 is restricted from moving toward the main body 21. That is, the movement of the moving unit 22 from the first position to the second position is restricted. Therefore, it is possible to prevent the moving unit 22 from unintentionally moving to the second position due to some impact or load. Then, when it is desired to move the moving unit 22 to the second position, the knob portion 952 is pulled. As a result, the cutout portion 953 is widened, and the stopper body 951 can be removed from the moving unit 22. The configuration of the stopper 95 is not particularly limited as long as it is detachably arranged between the base 31 of the operation unit 3 and the main body 21 when the moving unit 22 is in the first position. Therefore, the operation unit 3 does not have to be configured as shown in FIG. 42 , and may be configured to protrude like a flange from the outer circumferential surface of the moving unit 22, and the stopper 95 can be arranged between such an operation unit and the main body 21.

[0137] <c-10> In the above embodiment, when the moving part 22 is in the second position, this state can be maintained. For example, as shown in FIG. 44, the operating part 3 can be provided with a cylindrical extension part 39 extending downward from the periphery of the base part 31. As shown in FIG. 45 and FIG. 46, the lower end part of this extension part 39 is configured to contact the base 1 when the moving part 22 is in the second position. This allows the operating part 3 to be stably held on the base 1. Therefore, for example, when an impact or load is applied from the lateral direction, it is possible to prevent the operating part 3 and the moving part 22 from shifting or floating up. Therefore, it is possible to prevent the needle member 4 inserted into the skin from unintentionally coming out of the skin or the needle member 4 from moving while inserted into the skin.

[0138] The configuration of the extension part 39 is not particularly limited, and it need not be cylindrical as long as it is disposed between the base 31 of the operation part 3 and the base 1 when the moving part 22 is in the second position. That is, it is sufficient to configure the extension part 39 so that the lower end of the extension part 39 is located near the lower end of the main body part 21 when the moving part 22 is in the second position. That is, it can be configured so that at least a part, preferably most part of the main body part 21 is covered by the extension part 39 in the second position. For example, the entire operation part 3 including the base 31 and the extension part 39 may be mushroom-shaped, dome-shaped, or the like. Also, as described later, when the base 1 is not provided, the lower end of the extension part 39 is located near the lower end of the main body part 21 when the moving part 22 is in the second position, and is close to or in contact with the skin, so that the operation part 3 can be prevented from slipping as described above.

[0139] Further, the drug line 5 for supplying a drug to the needle member 4 is connected to the base 31 of the operation unit 3, and for example, as shown in Fig. 47, a hole 391 or a notch can be formed in the extension part 39, and the tube 6 can be fixed so as to be connected to the second passage 321 of the fixed part 32. This allows a connector 605 provided at one end of the tube 6 to be connected to the drug line 5, and a drug can be supplied to the needle member 4. The drug line 5 can also be directly connected to the fixed part 32.

[0140] <c-11> In the above embodiment, the moving part is held in the first position by the material, shape and dimensional design of the moving part 22, the connecting part 23 and the main body part 21. However, the present invention is not limited to this, and the moving part 22 may be configured not to be held in the first position without application of an external force. In this case, the moving part 22 can be held in the first position by using the above-mentioned stopper 95. That is, in such a drug administration device, for example, when the stopper 95 is removed from the state of FIG. 43, the moving part 22 moves from the first position to the second position without application of an external force, and the needle punctures the skin and administration is started, as shown in, for example, FIGS. 5A and 5B. After administration is completed, the entire drug administration device can be peeled off from the skin, or the fixing part 32 can be removed from the moving part 22 and then the drug administration device can be peeled off from the skin.

[0141] In the above embodiment, the force required to move the moving part 22 from the second position to the first position (hereinafter referred to as F2) is designed to be larger than the force required to move the moving part 22 from the first position to the second position (hereinafter referred to as F1). Note that F1 is the force required to push the moving part 22 downward, and F2 is the force required to pull the moving part 22 upward. However, the present invention is not limited to this, and the material, shape, and dimensions can also be designed so that F1=F2 or F1>F2. That is, in the present invention, it is sufficient that the moving part 22 is configured to be able to be held at the first position and the second position using various methods, such as appropriately changing the material, adjusting the shape of each member (for example, the main body part 21, the moving part 22, and the connecting part 23), or using other members such as stoppers.

[0142] <c-12> In the present invention, the shape of the main body 21 is not particularly limited, and in addition to the cylindrical shape in which the diameter increases toward the bottom as in the above embodiment, it can also be formed into a cylindrical shape with a constant inner diameter, a cylindrical shape in which the diameter decreases toward the bottom, a polygonal cylindrical shape, or an irregular shape. In any case, the axial direction means the direction of the axis of the cylindrical shape. In addition, the shape of the connecting part 23 is annular if the main body 21 is cylindrical, but if the main body 21 is polygonal cylindrical, the connecting part 23 is formed into a polygonal shape in plan view accordingly.

[0143] <c-13> In the present invention, the shape of the base 31 of the operation unit 3 is not particularly limited, and may be a shape other than a disk shape, and may be a rectangular shape, a polygonal shape, or an irregular shape. The outer shape of the base 31 of the operation unit 3 may be the same as or smaller than the end (first end) on the upper end side of the main body 21. This prevents the base 31 from protruding radially from the main body 21 when in the second position, and reduces the risk of the drug administration device coming off the skin due to rubbing or getting caught on the base 31 and clothing when the drug administration device is attached to the skin.

[0144] <c-14> The drug administration device has at least the main body 21, the connecting part 23, the moving part 22, and the needle member 4, and is sufficient as long as it is configured so that the drug line 5 can be directly or indirectly connected to the needle member 4. That is, the base 1 is not necessarily required, and the axial end (second end) of the main body 21 can be directly attached to the skin. Also, as shown in FIG. 26, a recess can be formed in the lower end of the main body 21 to make it easier to remove from the skin. In this case, an adhesive material can be applied to the end of the main body 21 other than the recess, or an adhesive sheet or sticker can be disposed. Therefore, in addition to the presence or absence of the operation part 3, the shape and material of each member can be appropriately changed. For example, the materials of the main body 21, the moving part 22, and the connecting part 23 are not particularly limited as long as the moving part 22 can be moved between the first position and the second position. Therefore, in addition to the soft resin material such as the above-mentioned elastomer, for example, resin materials such as hard resins such as polypropylene, polyethylene, and polyethylene terephthalate, and metals can be formed from various materials. Furthermore, the main body 21, the moving part 22, and the connecting part 23 do not necessarily have to be formed integrally, and can also be formed by assembling a plurality of materials.

[0145] In each of the above embodiments, the moving part 22 is configured to be housed in the main body part 21 when in the second position, but it does not necessarily have to be housed. That is, as long as the needle member 4 is inserted into the skin in the second position, the moving part 22 may be located outside the main body part 21. In this case, the shape of the connecting part 23 is adjusted, and the connecting part 23 is formed long so that the moving part 22 is disposed outside the main body part 21 in the second position. However, since the moving part 22 becomes compact when housed in the main body part 21 in the second position, it is preferable that at least a part of the moving part 22 is housed in the main body part 21. In addition, the tip shape of the needle member is not particularly limited, and a known tip shape can be adopted.

[0146] <c-15> In the above-mentioned drug administration device, in order to move the moving part 22 from the first position to the second position perpendicular to the skin, in other words, to puncture the skin perpendicularly with the needle member 4, a guide member (not shown) for moving the moving part 22 (or the needle member 4) approximately perpendicular to the skin can be provided around the moving part 22. The guide member can be provided, for example, in the internal space of the main body part 21.

[0147] <c-16> In the above-mentioned drug administration device, in order to prevent the needle member 4 from being left in the skin due to needle breakage during puncturing, for example, as shown in FIG. 48, a flange portion 41 can be provided on the outer peripheral surface of the needle member 4. When the moving part 22 is in the second position, the flange portion 41 can be provided in the area of ​​the needle member exposed to the outside between the fixed part 32 and the skin S. As a result, even if the needle breaks during puncturing and the tip of the needle member 4 remains in the skin S, the flange portion 41 is outside the skin S, so that the flange portion 41 can be grasped and the needle member 4 can be easily removed from the skin S. In addition, by setting the position of the flange portion 41 so that the flange portion 41 contacts the skin during puncturing, the puncturing length is the length from the flange portion 41 to the tip of the needle member 4, and the puncturing length can be more strictly controlled. Note that the flange portion 41 does not have to be provided on the entire outer peripheral surface of the needle member 4, and may be a member that protrudes radially outward from a part of the outer peripheral surface of the needle member 4. Furthermore, when the flange portion 41 protrudes radially outward from a part of the outer circumferential surface of the needle member 4, as shown in Fig. 48, the flange portion 41 is provided at a position close to the skin S of the needle member 4, but is not limited to this position and can be provided at a position close to the fixed portion 32 of the moving part 22 or the operating part 3, for example. In other words, the flange portion 41 only needs to be provided between the skin S and the fixed portion 32.

[0148] <c-17> By configuring the connecting portion with an elastic member such as a leaf spring, it is possible to control the movement of the moving portion. Several embodiments will be described below.

[0149] <c-17-1> The example of the drug administration device shown in FIG. 49A and FIG. 49B includes a cylindrical main body 21 and a moving part 22 to which a needle member 4 capable of moving up and down inside the main body 21 is attached. These can be integrally formed, for example, from a resin material such as hard resin, but can also be formed by combining different materials. The upper end of the inner wall surface of the main body 21 and the moving part 22 are connected by a connecting part 23 made of a leaf spring-like elastic member. More specifically, as shown in FIG. 49B, when the moving part 22 is in the second position where the moving part 22 enters the inside of the main body 21 and the needle member 4 protrudes from the lower opening of the main body 21, the connecting part 23 extends in a horizontal state without a load. On the other hand, as shown in FIG. 49A, in the first position where the moving part 22 has moved upward so that the needle member 4 is separated from the skin, the connecting part 23 is curved upward and a load is applied to urge the moving part 22 downward. 49A, a stopper 29 is detachably attached to the lower end of the moving part 22. The stopper 29 is a member that is bridged between the opposing upper end of the main body 21 and the lower end of the moving part 22, sandwiching the moving part 22 therebetween, thereby restricting the moving part 22 from moving downward. The configuration of the stopper is not particularly limited, and it may be anything that can hold the moving part 22 in the first position.

[0150] Then, when the stopper 29 is removed from the first position, the moving part 22 is urged downward by the connecting part 23 and moves to the second position as shown in FIG. 49B. Therefore, when the moving part 22 is in the first position, the opening at the bottom of the main body part 21 is attached to the skin, and when the stopper is removed from this state, the moving part 22 moves downward, and the needle member 4 can be pierced into the skin. In the configuration of FIG. 49, the moving part 22 moves up and down while being restrained by the leaf spring-like connecting part 23, so that the stroke during puncturing can be stabilized. Therefore, the needle member 4 can be pierced more accurately into the target puncturing position. In addition, since the leaf spring is arranged in the vertical direction, the urging force is strong, and this allows the needle member 4 to be firmly inserted into the skin. The shape of the elastic member is not particularly limited. For example, as shown in FIG. 50, when the leaf spring constituting the connecting part 23 is arranged to extend horizontally, the spring force is weaker, but the force for holding the moving part 22 in the first position is also weaker, so the load on the connecting part 23 itself is also smaller, and the possibility of malfunctions such as the connecting part 23 breaking or the main body part 21 being damaged is low.

[0151] <c-17-2> In the present invention, the moving part 22 can be configured to move outside the main body part. For example, in the example of FIG. 51, the plate-shaped main body part 21, the connecting part 23 made of a leaf spring-like elastic member extending horizontally from the lower end of the plate-shaped main body part 21, and the moving part 22 attached to the tip of the connecting part 23 are provided. These can be integrally formed from a resin material such as hard resin, but can also be formed by combining different materials. The moving part 22 is formed in a cylindrical shape, and a flange part 229 protruding horizontally is provided on the upper surface. In addition, a needle member 4 protrudes downward from the lower surface of the moving part 22. Furthermore, a rectangular parallelepiped platform part 776 is attached to the upper surface of the main body part 21, and a holding member 755 extending horizontally is attached to the side surface of the upper end of the platform part 776. This holding member 755 is disposed above the connecting part 23, and a notch 756 is formed at the tip.

[0152] FIG. 51A shows a state where the moving part 22 is in the second position. In this state, the connecting part 23 extends horizontally and no load is applied. At this time, the needle member 4 is designed to be pierced into the skin. Then, as shown in FIG. 51B and FIG. 51C, the moving part 22 is moved upward, and the flange part 229 of the moving part 22 is hooked on the notch 756 of the holding member 755. At this time, the connecting part 23 is bent upward and an elastic force acts, but the moving part 22 is hooked on the holding member 755 and held in the first position. Then, from this state, when the base part 776 is removed from the main body part 21 together with the holding member 755, the fixed state between the holding member 755 and the moving part 22 is released, and as shown in FIG. 51A, the connecting part 23 extends horizontally and the needle member 4 is pierced into the skin. It should be noted that the needle member 4 may be inserted into the skin by simply removing the moving part 22 from the holding member 755 while the base part 776 remains attached to the main body part 21.

[0153] According to the above configuration, since the main body 21 and the moving part 22 are separated, for example, when there is a defect such as inflammation at the site where the needle member 4 is inserted in the skin, the main body 21 can be attached to a site without such a defect. Therefore, when there is a defect in the skin, the main body 21, that is, this device, can be attached while avoiding that site. Furthermore, according to the above configuration, since the base part 776 is removed together with the holding member 755 at the time of puncturing (second position), the height of the entire device can be lowered, and defects such as the device coming off during puncturing can be reduced. Note that the configurations of the main body, the connecting part 23, and the holding member 755 are not particularly limited and can be changed as appropriate. Therefore, for example, the connecting part 23 and the holding member 755 can be interchanged. That is, the connecting part 23 can be attached to the upper end of the base part 776, and the holding member 755 can be attached to the main body 21. Then, while bending the connecting part 23 downward, the moving part 22 can be moved downward and hooked onto the holding member 755 arranged below.

[0154] <c-18> For example, a resilient elastic member such as rubber or a coil spring may be used as the connecting portion 23, and such an elastic member may be used to connect the main body portion 21 and the moving portion 22 to control the movement of the moving portion 22. Some examples will be described below.

[0155] <c-18-1> The example of the drug administration device shown in FIG. 52 has a hollow rectangular parallelepiped main body 21 with openings at the top and bottom, and the moving part 22 to which the needle member 4 is attached is housed in the main body 21. An elastic member 28 such as a spring is attached inside the main body 21 so as to connect the top of the moving part 22 to the top of the main body 21. The moving part 22 is configured to be able to take a first position in which the needle member 4 is housed in the main body 21 as shown in FIG. 52A) and a second position in which the needle member 4 protrudes from the opening at the bottom of the main body 21 as shown in FIG. 52B. When the moving part 22 is in the first position, the elastic member 28 is compressed, and the moving part 22 and the needle member 4 are held in the main body 21 by a stopper 29 detachably attached to the top of the main body 21. When the stopper 29 is removed from this state, the compressed elastic member 28 expands, and the moving part 22 moves downward. As a result, as described above, needle member 4 protrudes from the opening at the bottom of main body portion 21. Therefore, when moving portion 22 is in the first position, the opening at the bottom of main body portion 21 is attached to the skin, and stopper 29 is removed in this state, so that needle member 4 can be inserted into the skin. Moving portion 22 and stopper 29 can be detachably fixed together by a known method. Main body portion 21, moving portion 22, and needle member 4 shown here correspond to the drug administration portion of the present invention, and elastic member 28 in this example is also included in the drug administration portion.

[0156] <c-18-2> The example of the medicine injection device shown in Fig. 53 has a hollow rectangular parallelepiped main body 21 with openings at the top and bottom, and a moving part 22 to which a needle member 4 is attached is housed in this main body 21. In addition, an elastic member 28 such as a spring or rubber is attached so as to connect the lower part of the moving part 22 to the lower part of the main body 21. The moving part 22 is configured to be able to take a first position in which the needle member 4 is housed in the main body 21 as shown in Fig. 53A, and a second position in which the needle member 4 protrudes from the opening at the bottom of the main body 21 as shown in Fig. 53B.

[0157] When the moving part 22 is in the first position, the elastic member 28 is stretched, and the moving part 22 and the needle member 4 are held in the main body part 21 by the stopper 29 detachably attached to the upper part of the main body part 21. When the stopper 29 is removed from this state, the stretched elastic member 28 contracts, and the moving part 22 moves downward. As a result, the needle member 4 protrudes from the opening at the bottom of the main body part 21, as described above. Therefore, when the moving part 22 is in the first position, the opening at the bottom of the main body part 21 is attached to the skin, and the stopper 29 is removed in this state, the needle member 4 can be inserted into the skin. The moving part 22 and the stopper 29 can be detachably fixed by a known method.

[0158] <c-18-3> The example of the drug administration device shown in FIG. 54 has a hollow rectangular parallelepiped main body 21 with an opening at the bottom, and the moving part 22 to which the needle member 4 is attached is housed in the main body 21. In addition, an elastic member 28 such as a spring is attached so as to connect the bottom of the moving part 22 to the bottom of the main body 21. Furthermore, the top of the main body 21 is elastically deformable, and fasteners 216 are provided on the opposing surfaces 211 and 212 of the main body, respectively, and both fasteners 216 can be fixed by pressing these opposing surfaces 211 and 212. The moving part 22 is configured to be able to take a first position in which the needle member 4 is housed in the main body 21 as shown in FIG. 54A, and a second position in which the needle member 4 protrudes from the opening at the bottom of the main body 21 as shown in FIG. 54B. The above-mentioned fastener 216 is disposed at a position facing the vicinity of the upper end of the moving part 22 in the first position.

[0159] When the moving part 22 is in the first position, the elastic member 28 is at a substantially natural length and no load is applied. From this state, when the fasteners 216 on the opposing surfaces 211, 212 of the main body 21 are pressed as described above, the moving part 22 is pushed downward and moves to the second position. When the opposing surfaces 211, 212 of the main body 21 come into contact with each other by fixing the fasteners 216, the internal space of the main body 21 narrows above the moving part 22 in the second position, so that the moving part 22 is restricted from moving upward and is held in the second position. At this time, the elastic member 28 is compressed, and the moving part 22 is urged upward by the elastic member 28, but since the opposing surfaces 211, 212 of the main body 21 are fixed by the fasteners 216 as described above, the upward movement is restricted. Therefore, when the movable part 22 is in the first position, the lower opening of the main body part 21 is attached to the skin, and from this state, the opposing surface of the main body part 21 is pressed and the movable part 22 is moved to the second position, whereby the needle member 4 can be inserted into the skin.

[0160] <c-18-4> In the example of the drug administration device shown in FIG. 55, the main body 21 has a hollow rectangular parallelepiped shape with an opening at the bottom, and the moving part 22 to which the needle member 4 is attached is housed in the main body 21. In addition, an elastic member 28 such as a spring is attached so as to connect the bottom of the moving part 22 to the bottom of the main body 21. Furthermore, the top of the main body 21 is elastically deformable. The moving part 22 is configured to be able to take a first position in which the needle member 4 is housed in the main body 21 as shown in FIG. 55A and FIG. 55B, and a second position in which the needle member 4 protrudes from the opening at the bottom of the main body 21 as shown in FIG. 56A and FIG. 56B. In addition, protrusions 225 protrude from both side surfaces of the moving part 22. The protrusions 225 protrude from both side surfaces of the moving part 22 by springs not shown. However, when the moving part 22 is in the first position, each of the protruding parts 225 comes into contact with the first side surface 211 and the second side surface 212 of the main body part 21 that face the protruding part 225, and further protrusion is restricted. Furthermore, when the moving part 22 is in the second position, a through hole 218 is formed in each of the first side surface 211 and the second side surface 212 of the main body part 21, and the protruding part 225 protrudes from each through hole 218. That is, when the moving part 22 is in the second position, the protruding part 225 is pushed out by the spring and protrudes from the through hole 218. As a result, the moving part 22 is held in the second position.

[0161] When the moving part 22 is in the first position, the elastic member 28 has a substantially natural length and is not subjected to a load. When the third side surface 213 and the fourth side surface 214 perpendicular to the first side surface 211 and the second side surface 212 of the main body part 21 are pressed from this state, the third side surface 213 and the fourth side surface 214 approach each other, and the moving part 22 is pushed downward and moves to the second position. When the moving part 22 moves to the second position, as described above, each of the protruding parts 225 protrudes from each of the through holes 218, and the moving part 22 is held in the second position. At this time, the elastic member 28 is compressed, and the moving part 22 is urged upward by the elastic member 28, but since the protruding parts 225 protrude from the through holes 218 as described above, the upward movement of the moving part 22 is restricted. Therefore, when the movable part 22 is in the first position, the lower opening of the main body part 21 is attached to the skin, and from this state, the third side 213 and the fourth side 214 of the main body part 21 are pressed, whereby the needle member 4 can be inserted into the skin.

[0162] <c-18-5> In the example of the drug administration device shown in FIG. 57, the moving part 22 has a cylindrical moving part 22 with an opening at the bottom, and a needle member 4 extending downward is attached to the upper surface of the internal space of the moving part 22. The needle member 4 protrudes from the opening at the bottom of the moving part 22. The moving part 22 is capable of housing a cylindrical main body 21, and an elastic member 28 such as a spring is attached to connect the upper part of the main body 21 to the upper surface of the internal space of the moving part 22. The main body 21 is formed with a through hole 219 extending in the vertical direction, and the needle member 4 is inserted through the through hole 219. The moving part 22 is configured to be able to take a first position above the main body 21 as shown in FIG. 57A, and a second position in which the moving part 22 moves downward and houses the main body 21 in the internal space of the moving part 22 as shown in FIG. 57B. When moving part 22 is in the first position, elastic member 28 is extended, and needle member 4 is housed in through hole 219 of main body part 21 and does not protrude from the bottom of main body part 21. In order to hold moving part 22 in the first position, a stopper 29 is attached to the outer circumferential surface of main body part 21 to prevent moving part 22 from moving downward.

[0163] An adhesive material can be provided on the underside of the main body 21 for fixing to the skin. After the main body 21 is adhered to the skin by this adhesive material, when the stopper 29 is removed in the first position, the elastic member 28 contracts, and the moving part 22 is pulled downward, as shown in FIG. 57B. This causes the needle member 4 to protrude downward from the through hole 219 of the main body 21. Therefore, when the moving part 22 is in the first position, the underside of the main body 21 is attached to the skin, and when the stopper 29 is removed from this state, the needle member 4 protrudes from the main body 21, and the needle member 4 can be inserted into the skin. The main body 21 and the skin can be fixed to each other by a material other than an adhesive material, and can be fixed by a tape as described above.

[0164] <c-18-6> The example of the drug administration device shown in FIG. 58 and FIG. 59 has a cylindrical main body 21 with an opening at the bottom, and a cylindrical moving part 22 to which a needle member 4 is attached is housed in the main body 21. An elastic member 28 such as a spring is attached so as to connect the top of the moving part 22 to the upper surface of the internal space of the main body 21. As a result, the moving part 22 is biased downward by the elastic member 28. A protrusion 225 is provided on each of the opposing side surfaces of the moving part 22. A slit 217 is formed on each of the opposing side surfaces of the main body 21, and the protrusion 225 of the moving part 22 protrudes from each slit 217 to the outside of the main body 21. Each slit 217 is formed in an L-shape having a first part 217a extending horizontally and a second part 217b extending downward from one end of the first part 217a. The movable portion 22 is configured to be capable of taking a first position in which the needle member 4 is housed in the main body portion 21, as shown in Figures 58A and 58B, and a second position in which the needle member 4 protrudes from an opening at the bottom of the main body portion 21, as shown in Figures 59A and 59B.

[0165] When the moving part 22 is in the first position, the elastic member 28 is compressed and each protrusion 225 is disposed at the first portion 217a of each slit 217. As a result, the downward movement of the protrusion 225 is restricted, and the moving part 22 is held at the first position. From this state, when the cylindrical moving part 22 is rotated to move the protrusion 225 in the horizontal direction and to the upper end of the second portion 217b of the slit 217, the protrusion 225 becomes movable downward along the second portion 217b. As a result, the moving part 22 is pushed downward by the elastic member 28 and moves to the second position. When the protrusion 225 moves to the lower end of the second portion 217b, further downward movement is restricted, and the length by which the needle member 4 protrudes from the main body part 21 is held constant. Therefore, when the movable part 22 is in the first position, the lower opening of the main body part 21 is attached to the skin, and from this state, the protruding part 225 is moved horizontally, whereby the movable part 22 moves downward and the needle member 4 can be inserted into the skin.

[0166] <c-18-7> The example of the drug administration device shown in FIG. 60 has a hollow rectangular parallelepiped main body 21 with an opening at the bottom, and a moving part 22 to which a needle member 4 is attached is housed in the main body 21. An elastic member 28 such as a spring is attached so as to connect the top of the moving part 22 to the top of the internal space of the main body 21. As a result, the moving part 22 is biased downward by the elastic member 28. A plate-shaped stopper 29 that holds the needle member 4 is detachably attached to the lower end of the main body 21. The moving part 22 is configured to be able to take a first position in which the needle member 4 is housed in the main body 21 as shown in FIG. 60A, and a second position in which the needle member 4 protrudes from the opening at the bottom of the main body 21 as shown in FIG. 60B.

[0167] When moving part 22 is in the first position, elastic member 28 is compressed, the tip of needle member 4 contacts stopper 29, and the downward movement of needle member 4 and moving part 22 is restricted. When stopper 29 is removed from this state, moving part 22 is pushed downward by elastic member 28 and moves to the second position. Therefore, when moving part 22 is in the first position, if the opening at the bottom of main body part 21 is attached to the skin and stopper 29 is removed from this state, moving part 22 moves downward, and needle member 4 can be inserted into the skin.

[0168] <c-18-8> In the drug administration device shown in Fig. 60, the configuration of the stopper is not particularly limited, and various known configurations can be applied. For example, as shown in Fig. 61, a stopper 29 is provided that contacts the tip of the needle member 4 when the moving part 22 is in the first position (Fig. 61A). This stopper 29 is rotatable, and can be rotated from outside the main body part 21. Therefore, when the needle member 4 is in the first position, if the stopper 29 is rotated to release the contact with the needle member 4, the moving part 22 is pushed downward by the elastic member 28 and moves to the second position (Fig. 61B).

[0169] <c-18-9> As shown in FIG. 62, a stopper 29 consisting of two parts is provided at the bottom of the main body 21. The two parts 29a, 29b are movable in the horizontal direction, and when the two parts 29a, 29b are close to each other and overlap, they come into contact with the needle member 4 in the first position. This causes the moving part 22 shown in FIG. 62A to be held at the first position. In addition, both ends of a wire 27 are fixed to the parts 29a, 29b of the stopper 29. The wire 27 is hooked on rollers 275 provided on both sides of the main body 21, and the middle part of the wire 27 protrudes upward from the top of the main body 21. A fixture 279 is attached to this protruding part.

[0170] With this configuration, when the fixture 279 is pulled upward, the wire 27 is also pulled upward. This causes the portions 29a, 29b of the stopper 29 fixed to both ends of the wire 27 to move away from each other. As a result, the contact between the stopper 29 and the needle member 4 shown in FIG. 62B is released, the moving part 22 moves downward, and the needle member 4 protrudes from the main body 21.

[0171] <c-19> The movement of the moving part can also be controlled by pressing the main body part. The example of the drug administration device shown in FIG. 63 has a hollow rectangular parallelepiped main body part 21 with an opening at the bottom, and the moving part 22 to which the needle member 4 is attached is housed in this main body part 21. The moving part 22 is held inside the main body part 21 so as to be movable up and down. In addition, in the main body part 21, a pair of surfaces 211 and 212 facing each other are plastically deformable. The moving part 22 is configured to be able to take a first position in which the needle member 4 is housed in the main body part 21 as shown in FIG. 63A, and a second position in which the needle member 4 protrudes from the opening at the bottom of the main body part 21 as shown in FIG. 63B.

[0172] When the moving part 22 is in the first position, it is pressed by the opposing surfaces 211, 212 of the main body 21, and the moving part 22 is held in the first position. From this state, when the upper portions of the opposing surfaces 211, 212 of the main body 21 are pressed and brought close to each other, the moving part 22 is pushed downward and moves to the second position. At this time, the opposing surfaces 211, 212 of the main body 21 are brought close to each other by plastic deformation above the moving part 22, and as a result, the internal space of the main body 21 above the moving part 22 is narrowed, so that the moving part 22 is restricted from moving upward and is held in the second position. Therefore, when the moving part 22 is in the first position, the opening at the bottom of the main body 21 is attached to the skin, and the opposing surfaces 211, 212 of the main body 21 are pressed from this state, and the needle member 4 can be inserted into the skin.

[0173] <c-20> The means for moving the moving part can be configured as shown in FIG. 64, for example. The example of the drug administration device shown in FIG. 64 has a cylindrical main body 21 with an opening at the bottom, and the main body 21 houses the moving part 22 to which the needle member 4 is attached. The moving part 22 is rotatably held inside the main body 21, and a dial 28 for rotating the moving part 22 is attached to the outer circumferential surface of the main body 21. The moving part 22 is also attached to the needle member 4, and is configured to be capable of taking a state in which the needle member 4 is housed inside the main body 21 as shown in FIG. 64A, and a state in which the needle member 4 protrudes from the opening at the bottom of the main body 21 as shown in FIG. 64B.

[0174] That is, the rotational position of moving part 22 with needle member 4 housed inside main body part 21 is the first position, and moving part 22 is rotated from this position by dial 28, and the rotational position of moving part 22 when needle member 4 protrudes from main body part 21 is the second position. Therefore, when moving part 22 is in the first position, the opening at the bottom of main body part 21 is attached to the skin, and by rotating dial 28 from this state, needle member 4 can be inserted into the skin.

[0175] In addition, <c-17> ~ <c-20>In this embodiment, the configuration for supplying the drug to the needle member is not particularly limited, and it is sufficient that a tube member is connected to the moving part or the needle member.

[0176] <c-21> The configuration of the main body part is not particularly limited, and can be configured as shown in FIG. 65, for example. FIG. 65A is a perspective view of the drug administration device, and FIG. 65B is a perspective view of the drug administration device with the operation unit and the needle member removed. In the example of FIG. 65, the configuration of the main body part 21 is different from that of FIG. 1 of the above embodiment, and as shown in FIG. 65A, the main body part 21 can be configured to accommodate the movement unit 22 and the operation unit 3 when the movement unit 22 is in the second position. That is, as shown in FIG. 65B, the periphery of the main body part 21 is made bulky, and when the movement unit 22 is in the second position, the operation unit 3 is accommodated inside the main body part 21. As a result, the periphery of the operation unit 3 is surrounded by the main body part 21, and the upper surface of the operation unit 3 and the upper end of the main body part 21 are roughly aligned, and the operation unit 3 in the second position can be accommodated in the main body part 21. 65A, a cutout 219 may be formed in a portion of the periphery of the main body 21, and the side surface of the operation unit 3 may be exposed to the outside through the cutout 219. This allows a drug line (not shown) to be connected to the exposed side surface of the operation unit 3.

[0177] Also, as shown in FIG. 66, when the operating unit 3 is provided with an extension 39, a groove 115 can be formed on the upper surface of the base 1 so that the lower end of the extension 39 fits in it. This groove 115 can prevent the extension 39, the moving unit 22, and the needle member 4 from moving when the extension 39 is subjected to an external force. However, as shown in the figure, the extension 39 is not completely fixed by the groove 115, and the width of the groove 115 can be made slightly wider than the width of the lower end of the extension 39 so that the extension 39 moves slightly due to the external force. This makes it possible to absorb the force acting on the extension 39 and to suppress the force from being directly transmitted to the base 1. Therefore, it is possible to suppress the base 1 from peeling off from the skin.

[0178] In the example shown in FIG. 65, a rectangular base 1 is provided, and slits 118 are formed along the four sides of the base 1. The slits 118 are also provided to improve ventilation, and thus, when the base 1 is attached to the skin, the skin can be prevented from becoming steamy. Also, as shown in FIG. 67, a number of protrusions 119 may be provided on the lower surface of the base 1, thereby forming a gap between the lower surface of the base 1 and the skin. Alternatively, small holes may be formed in parts other than the parts where the protrusions 119 are formed to improve ventilation. Such a configuration for improving ventilation may also be provided in the main body 21 when the main body 21 is attached directly to the skin.

[0179] <c-22> As a method for supplying a drug, a drug administration device as shown in FIG. 68 can be configured. In the example of FIG. 68, the configurations of the base 1, the main body 21, the connecting part 23, the moving part 22, and the needle member 4 are not particularly limited, but are the same as those of FIG. 22, for example. In addition to this, a syringe 900 containing a drug is attached to the moving part 22, and the discharge port of the syringe 900 is communicated with the needle member 4. As a result, when the plunger of the syringe 900 is pressed after the moving part 22 moves to the second position, the drug is discharged from the syringe 900, and the drug is administered to the skin through the needle member 4. The syringe 900 for supplying such a drug can be appropriately applied to the other drug administration devices described above. Note that this syringe 900 can be another example of the storage part of the present invention.

[0180] <c-23> For example, in the example of Figure 4, a cylindrical internal space is formed in the main body 21 such that the movable part 22 can move up and down, but it is also possible to block part of the opening at the lower end of the main body 21 and form a through hole 219 large enough for the needle member 4 to pass through, as shown in Figure 69.

[0181] <c-24> In addition, in each embodiment, the needle member 4 can be made rotatable around its axis. For example, when a needle hole is formed on the side of the needle member 4 or the tip of the needle member 4 is cut obliquely, the needle member 4 can be rotated around its axis to change the radial discharge position of the medicinal liquid. This also makes it possible to adjust the liquid passing speed. In the case of such a configuration, for example, in FIG. 4, the operation unit 3 can be connected to the moving unit 22 so as to be rotatable around the axis of the needle member 4. This allows the circumferential position of the needle hole to be changed by rotating the operation unit 3 relative to the moving unit 22 after the needle member 4 has been punctured. In this way, when the position of the needle hole can be changed, it is necessary to fix the operation unit 3 to the moving unit 22 with tape or the like in order to fix the operation unit 3 to the moving unit 22 at a desired position, or to configure the operation unit 3 to be held at a predetermined rotational position relative to the moving unit 22.

[0182] <c-25> As shown in FIG. 70 and FIG. 71, a storage section 215 can be provided at the upper end of the main body section 21 so as to store the moving section 22 and the operation section 3 in the second position. This storage section 215 is formed in a cylindrical shape so as to extend the main body section 21 upward. By providing such a storage section 215, it is possible to prevent the moving section 22 and the operation section 3 in the second position from getting caught on clothing, etc. In addition, a notch 151 can be formed in the storage section 215 at a location where the drug line 5 passes. In addition, the position of the storage section 215 is not particularly limited, and it is sufficient that it is configured in a cylindrical shape so as to store the moving section 22 and the operation section 3 in the second position. Therefore, other than being provided at the upper end of the main body section 21, it can also be provided, for example, on the radial outside of the main body section 21. In addition, the example of FIG. 70 and FIG. 71 is based on the second embodiment, but it may be based on the first embodiment, or it may be applied to various examples shown in the modified examples. [Explanation of symbols]

[0183] 1 Base 12 Adhesive 14 Recess 2. Drug Administration Section 21 Main body 215 Storage unit 22 Mobile section 23 Connecting part 3 Control section 39 Extension 4 Needle member < / c-17>

Claims

1. 1. A drug delivery device for subcutaneously administering a drug, comprising: a tubular body configured to be placed on the patient's skin; a moving part to which at least one needle member protruding toward the skin side is removably attached; Equipped with The moving unit is configured to be reciprocally movable between a first position away from the skin and a second position close to the skin, When the moving part is in the second position, a tip part of the needle member is configured to be inserted into the skin, A drug delivery device configured such that the drug is expelled through a hole in the needle member.

2. The medication administration device according to claim 1 , wherein the moving part is configured to be held in at least one of the first position and the second position in the absence of application of an external force.

3. The drug administration device of claim 1 or 2, further comprising at least one connecting portion configured to connect the main body portion and the moving portion and to hold the moving portion in at least one of the first position and the second position.

4. A plurality of the connecting portions are provided, The drug administration device according to claim 3 , wherein the plurality of connecting portions are formed by a plurality of portions arranged radially around the needle member at predetermined intervals.

5. Each of the connecting portions is formed of an elastically deformable material and configured to be in a first state in the first position and in a second state in the second position; Each of the connecting portions is bent in the second state and is extended in the first state more than in the second state, The medication delivery device of claim 4 , wherein the coupling portion is configured to transition between the first state and the second state with elastic deformation.

6. The drug administration device according to claim 4 or 5, wherein the number of the connecting portions is 2 to 10.

7. The drug delivery device according to claim 3 , wherein the main body portion, the moving portion and the connecting portion are integrally formed.

8. The drug administration device according to claim 3 , wherein the main body portion, the moving portion, and the connecting portion are formed from an elastically deformable elastomer, hard resin, or metal.

9. The main body is formed in a cylindrical shape, The medication administration device according to claim 1 , wherein the moving portion is configured so that at least a portion of the moving portion is accommodated in the main body portion when the moving portion is in the second position.

10. A drug line for supplying the drug is configured to be attached, The drug delivery device of claim 1 , wherein the drug is supplied to the needle member from the drug line.

11. The medication administration device according to claim 1 , further comprising an operating part coupled to the moving part and capable of being held by a tool or a finger.

12. The medicine administration device according to claim 11 , wherein the operation portion is formed in a plate shape having an outer shape larger than that of the main body portion.

13. The device further includes an extension portion connected to the operation portion, The medication delivery device of claim 12 , wherein the extension portion is configured to cover at least a portion of the body portion when the moving portion is in the second position.

14. The operating portion is configured to protrude radially outward from an outer periphery of the moving portion, The pharmaceutical administration device of claim 11 or 13, further comprising a stopper that is removably arranged between the operating unit and the main body unit when the moving unit is in the first position, and that restricts the moving unit from moving to the second position.

15. The device further includes a storage section for storing a drug. A drug delivery device according to claim 1 , configured to supply drug from the reservoir to the needle member.

16. 16. A medication delivery device as claimed in any preceding claim, further comprising a base supporting the body portion and positioned against the skin.

17. The medication delivery device of claim 16, further comprising an adhesive disposed on at least a portion of the surface of the base that contacts the skin.

18. 18. The drug administration device according to claim 16, wherein a recess is formed on the peripheral surface of the base facing the skin so as to form a gap between the base and the skin.

19. A plurality of drug administration units are arranged on the base, The drug dispensing device according to claim 16 , wherein the drug dispensing portion comprises the main body portion, the moving portion, and the needle member.

20. The drug delivery device of claim 19 , wherein all the moving parts of the plurality of drug delivery parts are configured to be coupled.

21. a base for supporting the body portion and for being placed on the skin; The drug administration device according to claim 3 , wherein the base, the main body, the moving part and the connecting part are integrally formed from an elastomer.

22. the body portion is configured to be attached to the skin; The drug delivery device according to claim 1 , wherein the body portion has a recess formed therein such that a gap is formed between the body portion and the skin.

23. The medicine administration device according to claim 11 , wherein the needle member is fixed to the operating section, and the operating section is configured to be detachable from the moving section together with the needle member.

24. 24. The drug delivery device according to claim 1, further comprising a detachment means for detaching the needle member from the moving part.

25. The needle member further includes a cover member capable of covering at least the tip portion of the needle member.

25. A drug administration device as described in any one of claims 1 to 24, wherein when the moving part is in the second position, the tip of the needle member is exposed from the cover member, and after the moving part moves from the second position to the first position, the cover member is configured to cover the tip of the needle member and maintain the covered state.

26. The medication delivery device according to claim 25, wherein the tip of the needle member is configured to be covered by the cover member when in the first position before use.

27. The drug administration device according to claim 25 or 26, wherein the cover member is configured to be detachable from the moving part together with the needle part.

28. The drug administration device according to any one of claims 1 to 27, wherein the needle member has a thickness of 30 gauge to 35 gauge.

29. 29. The drug administration device according to claim 1, wherein the length by which the needle member protrudes from the surface fixed to the skin is 1 to 10 mm.

30. 30. The medication delivery device of claim 1, further comprising a housing configured to house at least the moving part when the moving part is in the second position.

31. The drug administration device according to claim 1 , wherein the needle member is configured to be rotatable around an axis of the needle member relative to the moving part.

32. At least one drug delivery device according to any one of claims 1 to 31; at least one drug container; a drug line for supplying a drug from the drug container to each of the drug administration devices; A drug delivery system comprising:

33. At least one drug delivery device according to any one of claims 1 to 31; a syringe capable of supplying a medicine to the needle member; A drug delivery system comprising:

Images